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Summary
In the analysis of genetic causation of disease and genetic eﬀects on quantitative traits
genome wide association studies (GWAS) on single phenotypes are widely applied. Al-
though it is known that the analysis of multiple phenotypes can help to identify new
genetic loci and improve the understanding of the shared genetic determination of phe-
notypes, not many studies analyze multiple phenotypes in a combined way. In this thesis
a new approach for the analysis of multiple phenotypes, named phenotype set enrich-
ment analysis (PSEA), is presented and successfully applied to two diﬀerent panels of
phenotypes.
PSEA was developed to analyze genetic eﬀects on sets of multiple phenotypes at a genome
wide scale. These predeﬁned sets are created using prior knowledge or criteria based on
single phenotype associations. PSEA calculates per gene an enrichment score based on
single phenotype associations. This score is tested for enrichment with a permutation
test. The algorithm uses known methodological elements from gene set enrichment anal-
ysis on GWAS data that were adapted to the situation of phenotype sets. Apart from
the basic algorithm two extensions were developed. One enables the internal identiﬁca-
tion of new phenotype sets that are tested for enrichment in addition to the predeﬁned
phenotype sets. With this approach, PSEA can use prior knowledge and generate new
hypotheses. A second extension allows the usage of GWAS summary statistics instead of
individual level genotypes and phenotypes. The algorithm was implemented in C with
MPI (message passing interface) parallelization and executed on a high performance com-
puter. It was applied to a panel of iron related phenotypes and blood count traits using
data of the population based KORA studies (cooperative health research in the region
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of Augsburg). PSEA identiﬁed additional genetic loci that had an eﬀect on blood and
iron traits and were not genome wide signiﬁcant in single phenotype GWAS on the same
data. These ﬁndings were conﬁrmed by results of published large meta-analyses. At sec-
ond, PSEA was applied to two panels of metabolite measurements including more than
hundred metabolites each. Predeﬁned phenotype sets were determined with a Gaussian
graphical modeling (GGM) approach. It was shown that PSEA can deal with large pan-
els of more than 150 phenotypes. Various ﬁndings from single phenotype GWAS on the
same data were conﬁrmed. The internal identiﬁcation of new phenotype sets unraveled
several unknown shared genetic eﬀects and provided valuable insight into the network of
metabolites.
Both applications showed that PSEA is able to identify additional loci that were not
found in single phenotype GWAS and improve the knowledge on phenotype relation and
underlying genetic basis. Moreover, the algorithm is ﬂexible, requires minimal assump-
tion and can easily be applied in various situations.
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Zusammenfassung
In der Analyse der genetischen Ursachen von Krankheiten oder Beeinﬂussung quan-
titativer Parameter werden häuﬁg genomweite Assoziationsstudien (GWAS) einzelner
Phänotypen verwendet. Obwohl die Analyse von multiplen Phänotypen zur Identiﬁka-
tion neuer genetischer Loci führen kann und zudem das Verständnis gemeinsamer Eﬀekte
auf verschiedene Phänotypen erweitert, werden in den meisten Studien Phänotypen sepa-
rat ausgewertet. In dieser Arbeit wird eine neue Methode, "Phenotype Set Enrichment
Analysis" (PSEA), vorgestellt und die vielversprechenden Ergebnisse ihrer Anwendung
auf zwei verschiedene Phänotyp-Datensätze präsentiert.
PSEA analysiert genomweit den Zusammenhang genetischer Loci und multipler Phäno-
typen, die zu Phänotyp-Gruppen (phenotype sets) zusammengefasst werden. Die vor-
deﬁnierten Phänotyp-Gruppen werden unter Verwendung von bestehendem Wissen oder
Ergebnissen aus einzelnen Phänotyp Analysen generiert. PSEA berechnet aus den As-
soziationen der einzelnen Phänotypen mit einer Gen Variante den sogenannten Enrich-
ment Score. Die Assoziationen einzelner Phänotypen mit der Gen Variante werden mit
diesem Score erfasst. Mit einem Permutationstest wird getestet, ob der Score höher
ist als zufällig erwartet. Für den Algorithmus wurden Elemente bekannter Methoden
der Gen-Gruppen Analyse (gene set enrichment analysis) in angepasster Form verwen-
det. Zusätzlich zum grundlegenden Ansatz wurden zwei Erweiterungen entwickelt. Zum
einen eine Strategie zur Identiﬁkation neuer Phänotyp-Gruppen mit PSEA. Die neu iden-
tiﬁzierten Phänotyp-Gruppen werden auf dieselbe Art analysiert wie die auf Grundlage
von vorherigem Wissen deﬁnierten Mengen. Somit besteht mit dieser Erweiterung die
Möglichkeit mit PSEA nicht nur Hypothesen bestehendenWissens zu testen sondern auch
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neue Hypothesen zu generieren. Die zweite Erweiterung ermöglicht die Verwendung von
GWAS Ergebnissen anstelle von Genotyp- und Phänotyp-Messungen pro Person. PSEA
wurde in C implementiert, mit MPI (message passing interface) parallelisiert und auf
einem Hochleistungs-Rechencluster ausgeführt. Die erste Anwendung von PSEA un-
tersuchte quantitative Phänotypen, die mit dem Eisenmetabolismus oder dem Blutbild
zusammenhängen. Dabei wurden zusätzliche genetische Loci identiﬁziert, die einen Ef-
fekt auf mehrere Blut- und/oder Eisenphänotypen zeigen, aber in GWAS der einzelnen
Phänotypen auf derselben Datengrundlage keinen genomweit signiﬁkanten Eﬀekt zeigten.
Publizierte GWAS und Metaanalysen großer Studien identiﬁzieren ebenfalls diese Loci
und bestätigen somit die Ergebnisse, die mit PSEA auf Grundlage einer geringeren An-
zahl Individuen gefunden wurden. Als zweite Anwendung von PSEA wurden zwei um-
fassende Datensätze von jeweils mehr als hundert Metaboliten analysiert. Die Phänotyp-
Gruppen wurden mit Gaußschen graphischen Modellen (GGM) bestimmt. Ergebnisse
bestätigten Assoziationen zwischen Gen Varianten und verschiedenen Metaboliten, die
aus den einzelnen GWAS der Phänotypen bekannt waren. Die interne Identiﬁkation
neuer Phänotyp-Gruppen ermöglichte die Identiﬁkation bisher unbekannter genetischer
Zusammenhänge und neue Erkenntnisse über das Zusammenspiel der Metaboliten.
Beide Anwendungen haben gezeigt, dass PSEA genetische Loci identiﬁzieren kann, die
bei der separaten Analyse der Phänotypen nicht gefunden wurden, und neue Erkenntnisse
über die gegenseitige Verﬂechtung der Phänotypen mit der zu Grunde liegende genetisch-
en Kondition liefert. Zudem ist der Ansatz ﬂexibel, kommt mit minimalen Annahmen
aus und kann einfach auf unterschiedliche Situationen angewendet werden.
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1. Introduction
Direct-to-consumer genetic test are controversially discussed in the scientiﬁc community
(Sivakumaran et al., 2011; Wade and Wilfond, 2006; Borry et al., 2010). The services
oﬀered by various companies provide genome wide or disease speciﬁc genetic testing.
One critical aspect of such tests is that genes can inﬂuence diﬀerent traits and addi-
tional eﬀects might be found in the future. Therefore, testing a genetic risk for a speciﬁc
disease or trait might lead to unintended information about another additional disease
(Sivakumaran et al., 2011; Wade and Wilfond, 2006). This could lead to ethical prob-
lems, especially if the second disease is untreatable or life threatening. This is only one
example for the importance of further insight in genetic eﬀects on multiple traits.
It is biological plausible that genes can have eﬀects on diﬀerent phenotypes. Gene pro-
ducts participate in various biological processes and one molecular function of a gene
can have multiple consequences (He and Zhang, 2006). A recent study ﬁnds that ap-
proximately 17% of all genes that are known to be associated with diseases or disease
traits have an eﬀect on multiple (independent) phenotypes (Sivakumaran et al., 2011).
In contrast to that joint analyses of multiple phenotypes are not often performed at the
moment. Mostly, genome wide association studies (GWAS) of single traits are applied for
analysis of genetic eﬀects on quantitative phenotypes and diseases. Some studies present
the results for several related phenotypes side by side in a comparing manner (Soranzo
et al., 2009), but most published GWAS are limited to single quantitative phenotypes or
one disease related trait (e. g. Kilpeläinen et al., 2011; Oexle et al., 2011).
This thesis presents a new method for the analysis of multiple phenotypes that analyzes
in parallel various sets of phenotypes for gene based association on a genome wide scale.
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1. Introduction
The understanding of the relation of genes and diﬀerent traits or diseases is one aim
of analyzing multiple phenotypes. Investigation of the underlying structure of diﬀer-
ent phenotypes and genes can give important insights into biological mechanisms and
connections. For example, the iron metabolism and the hematopoiesis are known to
be connected (Orkin and Zon, 2008). A joint analysis of iron and blood related traits
can improve the understanding of shared pathways. For large panels of intermediate
phenotypes like metabolomics a combined analysis can help to understand the hidden
connections and give insight into the function of metabolites and genes.
The second aim of multiple phenotype analysis is the identiﬁcation of new loci. If the
analysis is focused on one phenotype and more phenotypes are available, only a part of
the information is used. The shared information of correlated phenotypes can be advan-
tageous for these analyses. For example, if a gene is associated with several phenotypes,
but the eﬀect is too small to be detected in single phenotype GWAS, the association could
possibly be identiﬁed if the phenotypes are analyzed together. In other words, using more
phenotypes is equivalent with using a larger fraction of the available information.
The methods for multiple phenotype analysis are under development at the moment,
proposing various approaches (Shriner, 2012). Some authors developed multivariate al-
gorithms (Ferreira and Purcell, 2009; Liu et al., 2009) that are of limited use if many
phenotypes are under consideration. Moreover, they cannot be applied easily to situ-
ations where phenotype and genotype measurements for each person are not available.
Other approaches use the results of GWAS on single phenotypes (Gupta et al., 2011;
Huang et al., 2011; Yang et al., 2010). The focus of these algorithms is hypothesis gen-
eration, mining the data for sets of phenotypes associated with genetic loci. Another
strategy is to perform a phenotype screening for a previously deﬁned genetic locus, as
done in the phenome wide association scans (PheWAS) (Denny et al., 2010).
A ﬂexible approach for the genome wide analysis of multiple phenotypes that can deal
with large number of phenotypes, easily integrate prior knowledge, generate new knowl-
edge and manage minimal assumptions is lacking.
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This work describes a new strategy for the analysis of multiple phenotypes that sat-
isﬁes these requirements. The method tested phenotypes combined in phenotype sets
for enrichment at genes. Current methods for multiple phenotypes address either single
nucleotide polymorphism (SNP) level (Yang et al., 2010) or gene level (Huang et al.,
2011) eﬀects on multiple phenotypes. As genome wide scan calculations based on SNP
level imply a large multiple-testing burden and require a consideration of the underly-
ing LD structure, this work was focused on the gene based approach. The gathering of
phenotypes in phenotype sets had the advantage that prior knowledge could easily be
integrated and not many assumptions had to be made, except an approximately normal
distribution of the phenotypes. For the enrichment test methodological elements known
from gene set enrichment analysis approaches (Ackermann and Strimmer, 2009; Wang
et al., 2010) were adapted to the speciﬁc situation of investigation of phenotype sets.
In a nutshell, for each phenotype set and gene variant a score was calculated as a com-
bination of the statistics of the corresponding univariate analyses of all phenotypes in
the phenotype set. Then the enrichment of this score was evaluated by a permutation
test. An extension allowed the identiﬁcation of new phenotype sets. Another extension
enabled the usage of summary statistics of single phenotype GWAS instead of individual
phenotype and genotype measurements per person. This algorithm, named phenotype
set enrichment analysis (PSEA), is the ﬁrst adaption of a set enrichment approach to the
analysis of multiple phenotypes.
The method was applied to two diﬀerent studies of the cooperative health research in the
region of Augsburg (KORA): KORA F3 and KORA F4. The KORA cohorts are several
cohorts representative of the general population in Augsburg, Southern Germany and two
surrounding counties that were initiated as part of the world health organization (WHO)
monitoring cardiovascular disease (MONICA) study (Wichmann et al., 2005). From the
collected data genome wide genotyping, phenotypes related to iron metabolism, blood
cell counts and metabolite measurements were used. Replication analysis was performed
in TwinsUK data, which is an adult twin-registry (Andrew et al., 2001).
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In this thesis the development of the PSEA algorithm and its application to two diﬀerent
panels of phenotypes is described. Chapter two outlines the general method of PSEA and
two extensions. In chapter three the application to iron related phenotypes and blood
count traits is presented. The fourth and ﬁfth chapter report the results of an application
of PSEA to two large panels of metabolomics measurements (Biocrates and Metabolon)
using two diﬀerent kinds of metabolite set deﬁnition. The ﬁndings are summarized in
chapter six and discussed in terms of possibilities, limitations and further applications.
The general method of PSEA is pictured in chapter two. Therefore, the algorithm is
described in four main steps: calculation of gene based test statistics, calculation of
the enrichment score, permutation test and estimation. Subsequently, two extensions
of PSEA are presented. Those enabled the identiﬁcation of new phenotype sets and
the usage of GWAS summary statistics instead of individual phenotype and genotype
measurements. The chapter is closed by a discussion of some important methodological
elements of PSEA.
The third chapter deals with the application of PSEA to a panel of iron related phe-
notypes and blood count traits. For this selection of phenotypes it could be exploited
that many genes were known from previous publications to be associated with at least
one of these phenotypes as this knowledge was used for the evaluation of the results
of PSEA. The application of PSEA identiﬁed several signiﬁcant enrichments in KORA
F4 that could be replicated in KORA F3. Comparison with results from large meta-
analyses conﬁrmed the identiﬁed phenotype set enrichments. PSEA was able to ﬁnd
additional loci that could not be detected in single phenotype GWAS on the same data.
The extension of PSEA on GWAS summary statistics was applied to the same pheno-
types using GWAS summary statistics instead of individual genotype and phenotype
measurements. The results were similar to the original approach of PSEA on genotype
and phenotype measurements per person, but the extension resulted higher p-values.
Reasons for this observation are evaluated. For all results biological interpretation with
respect to published studies is given. Moreover, this outcome is discussed more generally
as a Proof-of-Principle of the PSEA strategy.
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The application of the general algorithm of PSEA to two large sets of metabolite pan-
els is described in chapter four. The metabolites were measured with two techniques
provided by Biocrates (BIOCRATES Life Sciences AG) and Metabolon for individuals
of KORA F4, used for discovery, and TwinsUK, used for replication. Metabolite sets
were determined with a Gaussian graphical modeling (GGM) approach that exploits the
partial correlation structure of the metabolites. Several metabolite sets were found to
be signiﬁcantly enriched and replicated. The results corresponded to biological plausi-
ble relations of gene function and its (by-)products and substrates. Known associations
from single phenotype GWAS were conﬁrmed. The chapter is closed by a discussion of
methodological aspects of the application of PSEA to metabolite panels and metabolite
set deﬁnition.
The ﬁfth chapter describes the application of the extension for identiﬁcation of new phe-
notype sets to the same metabolite data as in chapter four. Several new genetic loci
were found for an enrichment with new identiﬁed phenotype sets. Additional informa-
tion could be gained for known loci due to new identiﬁed phenotype sets. In the end
of this chapter the extension of PSEA and its ﬁndings are discussed with respect to the
situation of metabolomics data.
The last chapter summarizes the ﬁndings of PSEA and discusses its strengths and possible
limitations. Ways for integrating PSEA in an analysis pipeline are mentioned. Ideas for
modiﬁcations and extensions of PSEA are given as a perspective on further development
possibilities.
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2. Phenotype Set Enrichment Analysis
(PSEA)
The aim of PSEA is to identify associations between genes and a set of phenotypes. The
general method is a phenotype set based enrichment approach. This chapter describes
the development of PSEA using adapted elements of established gene set enrichment
approaches. First, the general algorithm for testing the enrichment of a phenotype set at
a gene is described. Afterwards, two extensions are presented, namely the identiﬁcation
of new phenotype sets that are likely to be enriched for a gene and the use of GWAS
summary statistics instead of phenotype and genotype measurements per person. The
chapter is closed by the critical reﬂection of some basic concepts of PSEA.
The algorithm of PSEA was recently published: Ried et al. (2012).
2.1. PSEA  General Algorithm
For the algorithm methods already used for gene set enrichment analysis and its appli-
cation to GWAS data (Efron and Tibshirani, 2007; Guo et al., 2009; Segrè et al., 2010;
Subramanian et al., 2005; Wang et al., 2007) were modiﬁed. Parallels of gene set en-
richment analysis and phenotype set enrichment analysis facilitated usage of the same
methodological approaches. Anyway, speciﬁc characteristics of the analysis of phenotype
sets had to be regarded. In the following description of the algorithm it is stated for each
step which elements were borrowed from gene set analysis approaches and how they were
modiﬁed. A schematic overview of the main steps of PSEA is given in Figure 2.1.
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2.1. PSEA  General Algorithm
Figure 2.1.: Schematic overview of the PSEA algorithm. P1, P2, P3 are pheno-
types, P.set1 and P.set2 denote phenotype sets. The strength of association
of a SNP or gene with the phenotypes is indicated by diﬀerent shadings of
red and blue, a darker colour representing a stronger association.
In the following pm with m ∈ {1, . . . , Npheno} is one phenotype of Npheno continuous
phenotypes, which are approximately normally distributed, and PS is a phenotype set
that is a selection of NPS phenotypes from p1,...,pNpheno.
Step 1: Gene Based Statistics
To test genes for enrichment of a phenotype set, a gene based statistic was required for
each phenotype. The positive test statistics of an association test for all SNPs mapped
to a gene were calculated (e.g. χ2-test statistic for testing the eﬀect estimate in a linear
regression). These statistics were combined to a gene-wise test statistic per phenotype.
Analogous to gene set enrichment methods for GWAS data (Guo et al., 2009; Wang
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et al., 2007), the maximal test statistic of all SNPs mapped to a gene was taken as the
gene based statistic t(gene, pm). All SNPs in the transcribed region and a surrounding
area of a 110 kilo base pairs (kb) upstream and 40 kb downstream were mapped to the
gene. This deﬁnition for assigning SNPs to genes was chosen as 99% of the expected
cis-expression quantitative trait loci (cis-eQTLs) are located within this interval (Segrè
et al., 2010; Veyrieras et al., 2008).
Step 2: Enrichment Score
The next step was the determination of the enrichment score (ES) for each combination
of phenotype set and gene. The ES was calculated as sum of the gene based statistics of
all phenotypes in the phenotype set:
ES(PS, gene) =
∑
pm∈PS
t(gene, pm) . (2.1)
This is a modiﬁcation for positive test statistics of the widely used maxmean statistic
(Efron and Tibshirani, 2007), which was presented as sumstat score for gene set enrich-
ment (Tintle et al., 2009).
Step 3: Permutation
For PSEA a so called self-contained test was applied. The self-contained approach tests
whether a phenotype set is enriched compared to sets of random phenotypes (Ackermann
and Strimmer, 2009; Wang et al., 2010). It ensures that the result of PSEA for one phe-
notype set is independent of other phenotype sets under consideration (more details in
the section 2.4).
If individual level phenotypes and genotypes are available, random phenotypes can be
generated by permutation of the values over all individuals. This was also proposed for
diﬀerent gene set enrichment approaches (Wang et al., 2007). A special requirement for
PSEA is that one has to preserve the correlation structure of the phenotypes. Other-
wise, sets of phenotypes and sets of permutated phenotypes would not be comparable.
Therefore, all phenotypes were permuted in the same way. An algorithmic formulation
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of the permutation scheme is given in the Appendix A.1. Based on each permutation
of the phenotypes the SNP-wise test statistics could be calculated. Analogous to the
calculations for the original phenotype values, gene based statistics per gene (compare
step 1) and the permutation ES (compare step 2) were derived
ES(j) (PS, gene) =
∑
pm∈PS
t
(
gene, p(j)m
)
. (2.2)
Thereby, the index (j) indicates a permutation with 1 ≤ j ≤ Nperm.
For estimations, where it is important that the ES were comparable for diﬀerent genes
and phenotypes sets, a normalized enrichment score (NES) can be used. This was cal-
culated by normalizing the ES with the mean and standard deviation of the ES for all
permutations (see Appendix A.2 for details).
Step 4: Statistical Signiﬁcance and Multiple Testing Corrections
Statistical testing was performed using empirical distributions generated by permutation
of phenotype values. Various methods have been applied for gene set enrichment analysis.
For example a permutation p-value can be used for estimation in PSEA.
Permutation p-value: The permutation p-value of the test if a phenotype set (PS*)
is enriched for a gene (gene*) was taken as the fraction of permutations for which the
permutation based ES is larger than the original ES
P (PS∗, gene∗) =
#j
[
ES (PS∗, gene∗) ≤ ES(j) (PS∗, gene∗)]
Nperm
. (2.3)
Thereby, the index j indicates the permutation (1 ≤ j ≤ Nperm) and #j means count
over all permutations. The signiﬁcance level needed to be corrected for the number of
phenotype sets times the number of genes. As the number of permutations was limited,
the p-value was not continuous but raised in steps of 1/Nperm.
Alternatively, the false discovery rate (FDR) and family wise error rate (FWER) could
be used (see Appendix A.2 for details).
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Implementation
The algorithm of PSEA was implemented in the programming language C with MPI
(message passing interface) parallelization. It was designed as a ﬂexible command line
based software. Phenotype data, information about phenotype sets and gene mapping
were processed from human readable ﬁles in plain text format. Genotypes in Impute
output format (Marchini et al., 2007) could be used as well as zipped or binary Impute
output format. The parallelization enabled calculation of enrichment for multiple genes in
parallel. For example the software was executed within the DEISA (Distributed European
Infrastructure for Supercomputing Applications) project on a supercomputer with 400
processes in parallel (see section 3.3).
2.2. Extension 1: Identiﬁcation of New Phenotype Sets
The basic algorithm of PSEA as described above tested only predeﬁned sets that were
speciﬁed by prior knowledge and used as input for PSEA. But if only predeﬁned phe-
notype sets are used, one could miss an important combination of phenotypes. This is
especially true as diﬀerent phenotype sets may be enriched for diﬀerent genes. Testing
all possible combinations of sets would raise the number of tests and is therefore often
not feasible. The identiﬁcation of new phenotype sets parallel to the testing of predeﬁned
sets enabled to analyze promising associations.
For each gene a threshold criterion based on single phenotype association results was
applied. All phenotypes that had gene based univariate test statistics higher than a
predeﬁned threshold were regarded as newly identiﬁed phenotype set for this gene. A
p-value threshold of 5 · 10−4 was applied. This threshold was used only for identiﬁcation
of a phenotype set. Testing for enrichment of the new identiﬁed set was done in the
same way as for the predeﬁned sets. Therefore, the usage of a threshold that was less
stringent than the univariate signiﬁcance level was permitted. This aimed to balance
between including phenotypes on which the gene has no eﬀect and missing phenotypes
on which the gene has an eﬀect.
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2.3. Extension 2: PSEA on GWAS Summary Statistics
A modiﬁcation of PSEA was developed that can use test statistics per SNP and phe-
notype from GWAS results if phenotype and genotype measurements for each person
are not available. The permutation strategy was the major element that had to be
adapted. Instead of permuting phenotype levels over all individuals, the test statistics
were permuted over all SNPs. Guo et al. (2009) proposed a similar approach for gene set
enrichment analysis. To preserve the correlation structure of the phenotypes, the vector
of the SNP-wise test statistics was permuted in the same way for all phenotypes. Gene
based test statistics and permutation ES were calculated as described above. Testing
was performed with p-value estimation (as presented in equation (2.3)).
There are two impacts that have to be considered for this permutation scheme: (A) the
distribution of test statistics might be inﬂuenced by associations of the phenotypes with
other genes and (B) the permutation of SNP-wise test statistics destroys the linkage dis-
equilibrium (LD) structure. In other words, (A) means that the vector of SNP-wise test
statistics might include more high test statistics than expected under the distribution
of the null hypothesis of no SNP phenotype association. In permutations these high
test statistics could lead to higher permutation ES and therefore reduce the number of
identiﬁed enrichments. Of course, this is dependent on the phenotypes in the consid-
ered phenotype set, especially on their strength of genetic associations and number of
associated SNPs. The eﬀect of the destroyed LD structure in the permutations could
also lead to higher permutation ES. That is because of the gene test statistics, which
were calculated as maximum of all SNP test statistics. By chance, the maximal test
statistic of independent SNPs will be higher than the maximal test statistic of dependent
SNPs. The eﬀect of these two impacts was studied exemplarily for the data of the ﬁrst
application (see section 3.3).
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2.4. Discussion of Methodological Design
Level and Power of PSEA are dicussed in the Appendix A.3
Eﬀect of SNP-Gene Mapping
As PSEA is a gene based approach, a SNP-gene mapping is needed. Such a mapping
deﬁnes which SNPs are analyzed as one locus in PSEA. Above, the strategy was proposed
to map all SNPs to a gene that are in the transcribed or a ﬂanking region of 110 kb
upstream and 40 kb downstream. This SNP-gene mapping was designed to cover not
only the transcribed region but also most cis-eQTLs (Segrè et al., 2010). Therefore,
it is reasonable in terms of creating a good representation of each gene. Due to the
overlapping deﬁnition of genes, the loci are not independent. To regard this overlapping
structure of genes in the evaluation of PSEA results, one can consider groups of genes that
are overlapping in at least one SNP (gene groups). For non genome wide applications
of PSEA the SNP-gene mapping could be reduced to independent genes of interest.
Moreover, PSEA can be applied with any other SNP-gene mapping if there are good
reasons for a modiﬁcation.
Apart from diﬀerent SNP-gene mapping methods, one could also extend PSEA on SNP
level. Technically, this approach would be possible analogous to the gene based analysis
by using single SNP statistics. There are two main situations where the SNP based
PSEA could gain more information than the gene based PSEA: First, PSEA on SNP
level enables to ﬁnd multiple independent loci that have an eﬀect on a phenotype set in
one gene. Second, SNPs with an eﬀect on a phenotype set could be identiﬁed, even if
they are not mapped to a gene. The main drawback of the SNP level calculation is that
it would strongly increase the number of tests. Moreover, many SNPs are in high LD
and therefore dependent of each other. To get reliable results, it would be reasonable
to reduce the analysis to independent SNPs. But the additional computational eﬀort
(more tests, LD analysis) might be higher than the possible ﬁndings. As an extension,
it is thinkable to use SNP level PSEA for analyzing genes for which gene level PSEA
identiﬁed signiﬁcant enrichments.
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Eﬀect of Permutation
The design of the permutation strategy has an important eﬀect on the results of PSEA.
It is obvious that the number of permutations has a direct impact on the PSEA results.
Especially, the signiﬁcance level for the p-value criterion is dependent on the number of
permutations as it determines the gradation and therefore the lowest possible p-value.
For application of Bonferroni-correction for PSEA the signiﬁcance level has to be ad-
justed for the number of genes and the number of phenotype sets under consideration.
That means for a genome wide run with approximately 20,000 genes, only one prede-
ﬁned phenotype set and 1,000 permutations the Bonferroni-corrected signiﬁcance level
0.05
20,000 = 2.5 · 10−6 is below the lowest possible p-value. It is not always feasible to cal-
culate a number of permutations that allows Bonferroni-correction, due to limitations in
computational ressources. The usage of a lower number of permutations can lead to false
positive ﬁndings.
A replication step helps to reduce the number of false positive ﬁndings that may result
from the higher signiﬁcance level. Another possibility is to increase the number of per-
mutations stepwise. Such a strategy starts with a low number of permutations (e.g. 100)
for all genes and increases the number of permutations only for those genes for which
at least one phenotype set showed a promising low p-value for the ﬁrst permutations.
Several steps can be performed unless a suﬃcient number of permutations is achieved or
the limitations of computational resources are reached. The results gained from the ﬁnal
step, the highest number of permutations, can be analyzed in a replication step.
One important aspect of the permutation strategy is that the correlation of phenotypes is
conserved. In the basic algorithm of PSEA on individual level genotypes and phenotypes
the phenotypes were permuted over all individuals. For application of PSEA to GWAS
results the test statistics of each phenotype were permuted over all SNPs. In both
cases all phenotypes were permuted in the same way so that the correlation structure
of the phenotypes was conserved. The conservation of correlation of phenotypes in the
permutation is important as the correlation of the phenotypes in the phenotype set
has an eﬀect on the ES and permutation ES. The permutation test compares the ES
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of phenotype sets based on original and permuted phenotypes. Diﬀerent correlation
structures in the original data and its permutation would change the results. In other
words, the permutation strategy ensures that the result for a phenotype set is not aﬀected
by modiﬁed correlation structure of the phenotypes in the set.
Self-Contained Test Strategy
It was mentioned above that PSEA follows a self-contained test strategy. That means
it tests a phenotype set for enrichment at a gene by comparison with a phenotype set
of random phenotypes. Each test for a phenotype set is independent from other pheno-
types (e.g. from other phenotype sets). The applied formula for the ES and permutation
scheme were designed to support this independence.
In contrast to that, in gene set enrichment often a comparative or nested approach is
applied (Ackermann and Strimmer, 2009; Wang et al., 2010). These strategies compare
the enrichment of a set with the enrichment of a random set of all elements under con-
sideration. Transferred to the phenotype set enrichment, a comparative approach would
compare a set of phenotypes with random sets of all phenotypes under consideration
and not with a set of random phenotypes. To gain reliable results, the comparative and
nested strategy needs a large panel of independent set elements. For gene set enrichment
often many independent genes are available but for phenotype set enrichment the number
of phenotypes is limited and phenotypes are often correlated. To ensure reliable results,
that are replicable in other studies with diﬀerent phenotype availability, it is important
that the enrichment analysis of a phenotype set is independent from other phenotypes in
the analysis. The application of the self-contained strategy warrants this and is therefore
the appropriate strategy for PSEA.
Other Approaches
PSEA belongs to the methods that combine statistics of univariate analysis. In com-
parison with multivariate analysis such approaches require in general fewer assumptions
about the phenotypes (Yang et al., 2010). Therefore, they can be transferred more eas-
ily to diﬀerent situations such as the use of either categorial or continuous phenotypes.
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PSEA could easily be modiﬁed for the analyses of binary traits or combinations of bi-
nary and quantitative traits. Besides PSEA, at least two other algorithms of that kind
have been published recently (Huang et al., 2011; Yang et al., 2010). Yang et al. (2010)
proposed a variation of O'Briens method (O'Brien, 1984) to combine univariate GWAS
results, which was realized on SNP basis in contrast to our gene based approach. The
program PRIMe (Huang et al., 2011) identiﬁes pleiotropic regions by scanning GWAS
results of multiple phenotypes for low p-values, whereupon the LD structure is taken into
account. PRIMe can identify diﬀerent phenotype sets for diﬀerent genes but it is not
designed for testing a panel of predeﬁned phenotype sets. Therefore, prior knowledge
cannot easily be integrated in the analysis.
PSEA is able to use prior knowledge and generate new knowledge. Moreover, it is easy
to apply and can deal with many phenotypes. These advantages are demonstrated in the
applications presented in the following chapters.
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In this chapter the application and results of PSEA to a panel of blood count traits
and iron related phenotypes are described. These phenotypes were a useful example
to demonstrate the abilities of PSEA, as several of these phenotypes are known to be
connected via the genesis of red blood cells. The fact that many genes were previously
known to be associated with at least one of these phenotypes (Figure 3.1) was exploited to
evaluate the results of PSEA. First the data used for the analysis is described. Then the
results of the application of PSEA are presented. After that the results will be discussed
not only with regard to their biological interpretation but also as a Proof-of Principle of
PSEA.
This application was recently published together with the general algorithm of PSEA:
Ried et al. (2012).
3.1. Iron and Blood Traits
PSEA was applied to genotype and phenotype data of two cohorts in the KORA study.
The KORA study consists of several cohorts representative of the general population in
Augsburg, Southern Germany and two surrounding counties that were initiated as part
of the WHO MONICA study (Wichmann et al., 2005). Ten years age-sex strata have
been sampled from the 25 to 74 year old population with a stratum size of 640 subjects.
In the KORA S3 study 4,856 subjects (response rate 75%), and in KORA S4 in total
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4,261 subjects have been examined (response rate 67%). 3,006 individuals participated
in a follow-up examination of S3 in 2004/05 which is called KORA F3. Follow-up for the
S4 survey was performed in 3,080 individuals in 2006/2008 (KORA F4). All study par-
ticipants underwent a standardized face-to-face interview by certiﬁed medical staﬀ and
a standardized medical examination including blood draw and anthropometric measure-
ments. For discovery a cohort of 1,814 randomly sampled, unrelated individuals of the
population based cohort KORA F4 was used. Replication was performed in a random
sample of 1,644 unrelated individuals of the independent cohort KORA F3 (Wichmann
et al., 2005).
Figure 3.1.: Iron and blood trait phenotype sets with published genes. This
ﬁgure summarizes the predeﬁned phenotype sets analyzed with PSEA. All
genes that have been reported to be signiﬁcantly associated with at least one
phenotype in previous GWAS or meta-analysis including multiple cohorts
are indicated. (trsf: transferrin, tfsat: transferrin saturation, stfr: soluble
transferrin receptor, ferri: ferritin, other abbreviations as given in the text)
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PSEA, using phenotype and genotype measurements per person, required four types of
input data: deﬁnition of phenotype sets, phenotype values for at least all elements of
the phenotype sets, genotypes, and a SNP-gene mapping. For the application of PSEA
to GWAS results one would not need phenotype values and genotype data but summary
results from the GWAS for all phenotypes under consideration.
Phenotypes: The method was applied to a set of fourteen phenotypes (Figure 3.1): Five
traits related to the iron metabolism (iron, ferritin, transferrin, transferrin saturation,
soluble transferrin receptor) and nine traits related to blood cells including six red blood
cell traits (haematocrit (HCT), haemoglobin (HGB), mean corpuscular haemoglobin
(MCH), mean corpuscular haemoglobin concentration (MCHC), mean corpuscular vol-
ume (MCV), red blood cell count (RBC)), one white blood cell trait (white blood cell
count (WBC)) and two platelet traits (mean platelet volume (MPV), platelet count
(PLT)) (see appendix for details on measurement methods (Table B.1) and population
statistics (Table B.2)). Outliers were excluded if they diﬀered more than three standard
deviations from the mean value. Residuals of a linear regression on each log-transformed
phenotype concerning age and sex were calculated and taken as phenotypic input.
Phenotype Sets: Six phenotype sets were tested for enrichment; three included various
combinations of iron traits and three included combinations of blood traits (Figure 3.1).
These sets were selected based on obvious relation (e.g. white blood cells vs. red blood
cells) and prior knowledge (iron intake and accumulation: iron and ferritin, iron trans-
port: transferrin, transferrin saturation and soluble transferrin receptor (Oexle et al.,
2011; Hentze et al., 2010)).
Genotypes: Genotyping for KORA F3 was performed with Aﬀymetrix 500K genome
wide SNP-array. The KORA F4 individuals were genotyped on Aﬀymetrix 6.0 SNP-
array. After SNP-wise and person-wise ﬁltering genotypes were imputed with Impute
v 1.0.0 (KORA F3)/Impute v 0.4.2 (KORA F4) (reference HapMap phase 2, release 22)
(Marchini and Howie, 2010). The analysis was restricted to SNPs that had a minor allele
frequency higher than 5%, call rate higher than 95% and imputation quality higher than
0.4.
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SNP-gene mapping: A number of 22,034 genes were downloaded from the UCSC (Univer-
sity of California Santa Cruz) genome browser (http://genome.ucsc.edu/) in RefFlat
format (NCBI (National Center for Biotechnology Information) build 36/hg18). All genes
that were assigned to more than one chromosome or had transcripts more than one mega
base pairs long were excluded (71 genes) (as done by Segrè et al., 2010). The genotyped
and imputed SNPs were mapped to the genes according to their position. Genes that did
not show any SNP assignments were excluded. Moreover, the analysis was reduced to
autosomal chromosomes. That resulted in a number of 20,801 genes. In the following, the
term gene is also used for the region in which SNPs were mapped to a gene, transcribed
region of a gene with the ﬂanking region of 110 kb upstream and 40 kb downstream.
Such gene regions may be overlapping and some SNPs were mapped to several genes.
The group of genes that were overlapping in at least one SNP is called gene group. For
the presented data, the 20,801 genes lead to 2,319 gene groups. For the analysis of the
LD eﬀect a SNP-gene mapping was generated that included only independent SNPs that
are approximately in linkage equilibrium with each other. LD pruning was performed
with PLINK (Purcell et al., 2007).
GWAS results: GWAS were calculated based on the described phenotype input and
genotypes. SNPTEST v 2.2.0 (Marchini et al., 2007) was used for the calculation of the
GWAS on the residuals for single phenotypes.
3.2. PSEA Results on Blood and Iron Traits
The selection of iron related phenotypes and blood traits enabled the usage of published
results from large GWAS and meta-analyses for the evaluation of PSEA results. The
results of enriched phenotype sets per gene were compared with published results of
single phenotype GWAS. A gene is named previously associated gene for a trait if a
SNP located in the gene (110 kb upstream to 40 kb downstream of the transcript) was
published in a meta-analysis with a genome wide signiﬁcant p-value (Benyamin et al.,
2009; Chambers et al., 2009; Kullo et al., 2010; Oexle et al., 2011; Soranzo et al., 2009;
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Tanaka et al., 2010). The previously associated genes named in the mentioned literature
were presented in Figure 3.1 (details in appendix Table B.3). Enrichment of phenotype
sets is neither limited to previously associated genes nor do all previously associated
genes show enrichment of a phenotype set. However, if the enrichment of a phenotype
set is signiﬁcant for a gene that was previously published to be associated with elements
of this phenotype set, it would be more likely a correct ﬁnding than the enrichment for
a randomly selected gene.
Results of PSEA on Genotypes and Phenotypes per Person
For the results presented below 1,000 permutations were performed. As the step size of
the p-values was determined by the number of permutations, the lowest p-value unequal
to zero (0.001 for 1, 000 permutations) was taken as signiﬁcance level. A phenotype set
is called enriched for a gene if the p-value was lower than 0.001. As more than 50 tests
were taken forward for replication, the replication p-value was set to 0.001.
For evaluation of PSEA results, the absolute count of genes that were identiﬁed by
PSEA to be associated with at least one phenotype set was considered (shortly named:
identiﬁed genes). The number of previously associated genes among these genes was
used to assess the number of presumably true positive ﬁndings (Table 3.1). Furthermore,
the number of corresponding gene groups was regarded as this number accounted for
the overlapping gene deﬁnition. 16% (43/272) of the genes that were identiﬁed were
previously associated genes and therefore presumably true positive ﬁndings. Similar was
observed for gene groups (15/70 ≈ 21% presumably true positive ﬁndings). One must be
aware that the testing correction for the p-value criterion was possibly not strict enough.
That fact could lead to a higher false positive rate. The replication step increased the
percentage of presumably true positive ﬁndings to 67%. In terms of gene groups it was
even 100%. But the increase in true positive rate was coincident with a decrease in
the absolute number of identiﬁed previously associated genes. The detailed results of
signiﬁcantly enriched and replicated phenotype sets identiﬁed by PSEA are presented in
Table 3.2.
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Table 3.1.: Number of PSEA results on blood and iron phenotypes. The number
of genes and gene groups that were identiﬁed with PSEA to be associated
with at least one predeﬁned phenotype set is presented. The column previous
denotes how many of the identiﬁed genes/gene groups were previously known
from published GWAS and meta-analyses.
PSEA on genotypes and phenotypes PSEA on GWAS results
KORA F4 replication in KORA F3 KORA F4
number of genes number of genes number of genes
identiﬁed previous identiﬁed previous identiﬁed previous
p < 0.001
gene 272 43 52 35 58 22
gene group 70 15 6 6 17 7
Identiﬁcation of New Phenotype Sets
The signiﬁcant and replicated results included one new phenotype set. The set, named
new set in Table 3.2, consisted of iron, soluble transferrin receptor, transferrin saturation,
MCH and MCV. It was signiﬁcantly enriched in KORA F4 at TMPRSS6 and the same
set was identiﬁed and replicated in KORA F3. Altogether, 296 new phenotype sets were
identiﬁed with PSEA in KORA F4, of which 162 were signiﬁcantly enriched. Apart from
the results presented in Table 3.1, many genes were identiﬁed to be associated only with
new identiﬁed phenotype sets. The percentage of gene groups that include a previously
associated gene among these identiﬁed gene groups is quite low (1.9%, data not shown).
Nevertheless, the replicated results showed that the identiﬁcation of new phenotype sets
can give valuable insight into phenotypic networks.
Comparison of PSEA with Single Phenotype GWAS
The ﬁndings of PSEA were compared with results of GWAS in KORA F4 on single
phenotypes (Table 3.2). For three genes (two independent gene groups) none of the single
phenotype GWAS on the blood and iron traits showed a signiﬁcant result in KORA F4.
Therefore, these genes would not have been found in GWAS in KORA F4 on single
phenotypes but were identiﬁed by PSEA with enrichment of a phenotype set. For the
remaining signiﬁcant and replicated enrichments at least one phenotype per set had a
genome wide signiﬁcant p-value (< 5 · 10−8) in the single phenotype GWAS.
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Table 3.2.: Replicated PSEA results on blood and iron phenotypes. Gene groups
are separated by background colour. If the enrichment of a phenotype set
was signiﬁcantly enriched and replicated for more than one gene of a gene
group, the gene with the highest NES is presented. The results for previously
associated genes that were part of a gene group for which a signiﬁcantly
enriched and replicated phenotype set was identiﬁed are also reported in the
table. Genes are marked with an asterisk if no SNP in the gene region has been
published with an association of blood or iron traits before. The signiﬁcance
level for discovery and replication was < 0.001. For each gene the p-value
and trait is given, that showed the lowest association p-value of all blood
respectively iron traits and all SNPs in the gene in KORA F4 single phenotype
GWAS. Gene names are indicated with bold letters if the minimal p-value of
the KORA F4 GWAS was not genome wide signiﬁcant (p-value < 5 · 10−8).
gene pheno.-set
PSEA results GWAS results
discovery replication KORA F4
KORA F4 KORA F3 blood traits iron tratis
p-value p-value phenotype p-value phenotype p-value
TMCC2 set_blood3 < 0.001 < 0.001 MPV 4.10 · 10−7 iron 0.0057
ARHGEF3 set_blood3 < 0.001 < 0.001 MPV 3.03 · 10−12 iron 0.0017
TF set_iron1 < 0.001 < 0.001 PLT 0.0025 transferrin 1.86 · 10−41
TF set_iron2 < 0.001 < 0.001 PLT 0.0025 transferrin 1.86 · 10−41
HFE set_iron1 < 0.001 < 0.001 MCH 1.41 · 10−5 trans. sat. 7.6 · 10−9
HIST1H1C set_iron1 < 0.001 < 0.001 MCH 1.41 · 10−5 trans. sat. 7.6 · 10−9
HFE set_iron2 < 0.001 < 0.001 MCH 1.41 · 10−5 trans. sat. 7.6 · 10−9
HIST1H1A set_iron2 < 0.001 < 0.001 MCH 1.41 · 10−5 trans. sat. 7.6 · 10−9
PCSK7 set_iron1 < 0.001 < 0.001 MCHC 0.0054 stfr 2.25 · 10−9
APOC3* set_iron1 < 0.001 < 0.001 HCT 0.0017 stfr 5.22 · 10−10
PCSK7 set_iron2 < 0.001 < 0.001 MCHC 0.0054 stfr 2.25 · 10−9
APOC3* set_iron2 < 0.001 < 0.001 HCT 0.0017 stfr 5.22 · 10−10
TMPRSS6 new set < 0.001 < 0.001 MCV 1.64 · 10−4 stfr 1.04 · 10−6
TMPRSS6 set_iron1 < 0.001 < 0.001 MCV 1.64 · 10−4 stfr 1.04 · 10−6
C22orf33 set_iron1 < 0.001 < 0.001 MCV 1.64 · 10−4 stfr 1.04 · 10−6
TMPRSS6 set_iron2 < 0.001 < 0.001 MCV 1.64 · 10−4 stfr 1.04 · 10−6
C22orf33 set_iron2 < 0.001 < 0.001 MCV 1.64 · 10−4 stfr 1.04 · 10−6
stfr: soluble transferrin receptor; trans. sat.: transferrin saturation
The newly identiﬁed phenotype set new set consist of iron, soluble transferrin receptor, transferrin saturation,
MCH and MCV.
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Comparison with Published Results
PSEA revealed that the set of MPV and PLT is enriched for gene groups including
ARHGEF3 or TMCC2. These two genes were previously published in a large meta-
analysis (N > 13,500) for an association with MPV. The alleles of the corresponding
SNPs that increased the MPV were found to decrease the PLT. ARHGEF3 was shown
to be involved in the regulation of platelet counts and volume (intracellular signaling)
(Soranzo et al., 2009). The region including TMCC2 was reported to be associated
with MPV but no candidate gene was identiﬁed (Soranzo et al., 2009). The results of
PSEA showed that the set of all ﬁve iron traits (iron_set1) and the set of transferrin
related traits (iron_set3: soluble transferrin receptor, transferrin and transferrin satura-
tion) were signiﬁcantly enriched and replicated for four gene groups including the genes
TF, HFE, TMPRSS6 and PCSK7. That corresponds to the associations that were pub-
lished in large meta-analysis on diﬀerent iron traits. HFE and TF were reported to be
associated with transferrin (Benyamin et al., 2009) and HFE and TMPRSS6 with iron
(Benyamin et al., 2009; Tanaka et al., 2010). Moreover, HFE as well as TMPRSS6 were
shown to have an indirect eﬀect on the soluble transferrin receptor via the transferrin
saturation. In contrast to that, the eﬀect of PCSK7 on soluble transferrin receptor was
presumed to be more direct (Oexle et al., 2011). The gene product of TMPRSS6 is
known to be involved in the regulation of levels of the peptide hormone hepcidin, which
is an important master regulator of iron homeostasis in humans (Soranzo et al., 2009).
Additionally, TMPRSS6 was identiﬁed in a large meta-analysis on blood traits to be
associated with MCH, MCV and MCHC (Kullo et al., 2010). The new identiﬁed pheno-
type set that was signiﬁcantly enriched for TMPRSS6 included ﬁve of the six mentioned
traits that were previously reported for TMPRSS6. The ﬁndings of PSEA correspond to
the published results from large meta-analyses.
Results for PSEA on GWAS Summary Statistics
PSEA was applied to KORA F4 GWAS results with 1,000 permutations of SNP based test
statistics. In the analysis of PSEA on GWAS results 58 genes in 17 gene groups were
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detected for which phenotype sets were signiﬁcantly enriched (p-value < 0.001; Table
3.2). The comparison with results of PSEA on genotypes and phenotypes showed that
all these genes, except two, were detected by PSEA on genotypes and phenotypes as well.
Vice versa, the p-values of PSEA based on GWAS results for the replicated ﬁndings of
PSEA on genotypes were considerably low (data not shown). In spite of the fact that the
absolute number of identiﬁed genes is lower in PSEA based on GWAS results, it could be
observed that the percentage of possibly true positive ﬁndings (22/58 ≈ 38 %) was higher
than for PSEA on genotypes. Despite the possible impacts on the permutation scheme,
PSEA on GWAS results still found a valuable amount of presumably true ﬁndings.
3.3. Discussion of PSEA Results
This application of PSEA to iron and blood phenotypes demonstrated that valuable
results can be achieved with PSEA. Findings from single phenotype analyses including
large numbers of individuals could be reproduced with PSEA despite the lower sample
size of the used KORA data.
PSEA Identiﬁes more than Single Phenotype GWAS
PSEA identiﬁed several signiﬁcant enrichments of the predeﬁned phenotypes sets at dif-
ferent genes. The comparison of the results with published ﬁndings of large meta-analyses
conﬁrmed that a considerably high amount of the ﬁndings of PSEA were likely to be true
positive ﬁndings. The application of PSEA to the given data identiﬁed several genes that
were not genome wide signiﬁcant in KORA F4 GWAS on the single phenotypes. In other
words, PSEA could identify more loci that have an eﬀect on multiple phenotypes than
single phenotype GWAS. From phenotype sets that were signiﬁcantly enriched for one or
several genes information regarding the connection of phenotypes could be gained. In this
application the observed connections were already known. However, in other situations
the enrichment of phenotype sets might help to understand the unknown interdependen-
cies of phenotypes.
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Extension 1: Newly Identiﬁed Phenotype Sets
The application showed that the identiﬁcation of new sets provided additional informa-
tion. For TMPRSS6 the information was gained that this gene has an eﬀect on MCH
and MCV apart from the eﬀect on iron parameters. None of the predeﬁned phenotype
sets consisted of a mixture of iron and blood phenotypes. Without the possibility to
identify new phenotype sets this interesting connection would have been missed.
The identiﬁcation of new phenotype sets in PSEA used a ﬁxed level of test statistics for
single phenotype association. A data driven estimation of this threshold may be a point
for further development.
Extension 2: Application of PSEA GWAS Results
The main beneﬁt of the extension of PSEA to GWAS results is the applicability to
situations where individual genotype and phenotype measurements are not available. In
the application to GWAS results of blood and iron phenotypes in KORA F4 revealed
similar results as for PSEA on genotypes and phenotypes per individuum.
It could be observed that the p-values of PSEA to GWAS results were a bit higher
and with this not all ﬁndings of PSEA on individual genotypes and phenotypes could
be found with the usage of GWAS results. This was mainly caused by the required
modiﬁcations of the permutation scheme. As mentioned above there were two aspects
that made the permutation scheme of PSEA on GWAS results less optimal than the
permutation scheme of PSEA on genotypes and phenotypes: (A) possibly inﬂated test
statistics distribution by association of phenotypes with other genes and (B) destroyed
LD structure by SNP permutation. These two aspects were studied in this application
to blood and iron phenotypes. For aspect (B) PSEA on GWAS results for a pruned
list of SNPs was considered. With pruned GWAS results more genes were found than
with PSEA on not pruned GWAS results. Apart from the increased absolute number of
genes, also rose the number of identiﬁed genes that were previously published (Appendix
Table B.4). Anyway, the percentage of previously published genes in all identiﬁed genes
was even higher in PSEA on not pruned GWAS results. The destroyed LD structure
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reduced the absolute number of identiﬁed genes but PSEA on GWAS results still led
to interesting results. The aspect (A) is highly dependent on the phenotypes under
consideration. For the present data, the percentage of genes that were identiﬁed by
PSEA on genotypes and with PSEA on GWAS results (pruned data) decreased with
the number of associated genes and strength of association of the phenotypes in the
phenotype set under consideration in the single phenotype GWAS (Appendix Table B.5
and Appendix Figure B.1)). But in many cases especially phenotypes with no strong
eﬀect on a single phenotype would be interesting to test for phenotype set enrichment.
For those phenotypes the eﬀect of (A) would be small.
The results showed that even with not pruned data and inﬂated test statistic distributions
PSEA on GWAS results can identify interesting gene phenotype set relations.
Computer Intensity
As mentioned above, the algorithm of PSEA was implemented with the programming lan-
guage C with MPI parallelization. The program was executed on the Edinburgh Parallel
Computing Centre (EPCC) supercomputing platform HECToR (High End Computing
Terascale Resources) phase 2a (12,288-processor Cray XT4) within a project of DEISA
(Distributed European Infrastructure for Supercomputing Applications). On 100 nodes,
each with four processes, a genome wide run with 2.8 million SNPs, 28,000 genes, 14 phe-
notypes for 1,814 individuals and six phenotype sets with 1,000 permutations took around
105 minutes per cohort. In terms of computer intensity of the permutation strategies
PSEA on GWAS results is clearly less demanding than PSEA on individual genotypes
and phenotypes. A genome wide run for the mentioned phenotypes and phenotype sets
on 2.18 million SNPs (only SNPs with good quality) took approximately 38 hours on one
core of an Intel core i7 975 extreme 3.33GHz, 24GB RAM Linux computer.
This application demonstrated, that PSEA can detect additional loci that were not found
with single phenotype GWAS on the same data. In situations were the relation of the
phenotypes is unknown, for example in metabolomics data, PSEA could also improve
the knowledge on the network of phenotypes.
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Predeﬁned Phenotype Sets
This chapter describes the application of the general algorithm of PSEA to two diﬀerent
panels of metabolomics data. It is shown that PSEA can improve the knowledge on
the complex and high dimensional network of intermediate phenotypes. Furthermore,
it demonstrates the ability of PSEA to cope with a large number of phenotypes. At
ﬁrst metabolomics data is described. A special aspect of this application is the genera-
tion of metabolite sets with the Gaussian graphical modeling (GGM) that uses partial
correlation between the metabolites. Data of KORA F4 was used for discovery and repli-
cation was performed in data from the TwinsUK study. The results of PSEA for both
metabolite panels are presented and selected results are discussed biologically. A more
methodological view on the application is given in the end of this chapter.
4.1. Metabolomics Data
For the analysis data from KORA F4 (described in section 3.1) was used as discovery co-
hort and data from the TwinsUK cohort as replication. The TwinsUK study is a British
adult twin-registry. The participants were recruited from the general population through
national media campaigns in the United Kingdom and were shown to be comparable
to age-matched population singletons in terms of disease related and lifestyle charac-
teristics (Andrew et al., 2001). Measurements of metabolomics data with two diﬀerent
technologies was performed in both cohorts.
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Biocrates Metabolites
A panel of 163 metabolites was measured for individuals of KORA F4 using electro spray
ionization tandem mass spectrometry with the AbsoluteIDQ kit (BIOCRATES Life Sci-
ences AG). Details of the measurement methods were described in previous publications
(Gieger et al., 2008; Illig et al., 2010). Metabolites that were not stable (experimen-
tal variance > 25%) in repeated measurements of some control samples were excluded.
Moreover, metabolites with more than 10% missing values were removed from the analy-
ses. Per metabolite extreme values (±5 standard deviations from mean value) were iden-
tiﬁed. Individuals that showed extreme values for more than three independent metabo-
lites (correlation < 70%) were excluded. Extreme values for remaining individuals were
set to missing. Missing values were imputed with the MICE algorithm (Multivariate
Imputation by Chained Equations; http://cran.r-project.org/web/packages/mice/
index.html) that was implemented in R (http://www.r-project.org/). After qual-
ity control 151 metabolites remained for further analyses. These 151 metabolites can
be grouped in ten metabolite classes including amino acids (14), hexoses (1), diﬀerent
carnitines (free carnitine (1), acylcarnitines (22), hydroxy- and dicarboxyacylcarnitines
(12)), sphingomyelins (9) and hydroxysphingomyelins (5) and diﬀerent forms of phos-
phatidylcholines (diacyl-phosphatidylcholines (36), acyl-alkyl-phosphatidylcholines (38),
lyso-phosphatidiylcholines (13)). A full list of all metabolites is given in the appendix
Table C.1. For 1,809 individuals in KORA F4 Biocrates metabolites and genome wide
genotypes were available.
For replication data from the TwinsUK cohort was used that had measurements for
metabolites with the same AbsoluteIDQ kit (BIOCRATES Life Sciences AG). The metabo-
lites underwent the same quality control as described for KORA F4. All 151 metabolites
passed the quality control in TwinsUK as well. 1,173 individuals with genotypes and valid
Biocrates metabolites measurements were used for further analysis. After reduction to
unrelated individuals 843 individuals remained in the analysis.
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Metabolon Metabolites
A diﬀerent set of 295 metabolites were measured for individuals of KORA F4 with a tech-
nique supplied by Metabolon. It used ultrahigh-performance liquid-phase chromatogra-
phy and gas-chromatography separation with tandem mass spectrometry (Evans et al.,
2009; Ohta et al., 2009). The measurement method was described in detail in a previous
publication (Suhre et al., 2011). 102 metabolites had more than 10% missing values
and were excluded from the analyses. Missing values for the remaining metabolites were
imputed with MICE (see description for Biocrates metabolites). The remaining 193
metabolites spanned diﬀerent super pathways including amino acids (52), carbohydrates
(10), cofactors and vitamins (7), energy (3) and lipid (90) pathway relevant compounds,
nucleotides (9), peptides (11) and xenobiotics (11). A full list of all 193 metabolites
together with additional information about the pathways they belong to is given in the
Appendix Table C.2. In total 1,768 individuals with valid Metabolon metabolites mea-
surements and genotypes could be used for further analysis.
The same technology was used to measure metabolites in TwinsUK data. Only metabo-
lites that passed quality control in KORA F4 were regarded. Individuals with more than
50% missing values were excluded. That led to 1,052 individuals with a maximal missing
rate of 21.16 %. Four metabolites that were present in KORA F4 had less than 300 valid
measurements in TwinsUK data. According to Suhre et al. (2011), 300 is the critical limit
of non-missing values to avoid false positive ﬁndings due to small sample size. There-
fore, these four metabolites were excluded from further analysis. In the remaining 189
metabolites the maximal missing rate per metabolite was 65.59%, which is equivalent to
362 valid measurements. To assure that most metabolite sets could be analyzed in the
replication, no further exclusion criteria for metabolites were applied. No imputation of
missing data was performed. After reduction to unrelated and genotyped individuals 705
individuals remained in the analysis.
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Deﬁnition of Metabolite Sets  Gaussian Graphical Modeling (GGM)
For the deﬁnition of phenotype sets for PSEA GGM was applied, which used the con-
ditional dependence between the variables (Krumsiek et al., 2011). The models were
estimated based on the partial correlation coeﬃcient of each pair of metabolites, which
is the pairwise Pearson correlation coeﬃcient conditioned against the correlation with
all other metabolites in the analyses. This approach was shown to be a valuable tool
for identiﬁcation of metabolite networks, which is able to distinguish direct form in-
direct associations (Krumsiek et al., 2011). Another advantage is that this estimation
of metabolite sets is independent from further information like availability of database
information. The analysis strategy was applied to the panel of all metabolite measure-
ments in KORA F4 that passed quality control and to all individuals with metabolite
measurements and genotypes. Metabolon and Biocrates metabolites were analyzed sep-
arately. Two partial correlation coeﬃcient cutoﬀ levels (0.3 and 0.45) were used. Both
cutoﬀs gave several metabolite sets. The sets were not overlapping for each cutoﬀ, but
sets gained from the higher cutoﬀ level were likely to be subsets of the sets gained with
the lower cutoﬀ level. This could be observed in the metabolite sets.
For Biocrates metabolites this approach led to 40 metabolite sets (presented in Figure
4.1). Two metabolite sets were deﬁned with both cutoﬀ levels. That means 38 diﬀerent
metabolite sets were found. The size of the metabolite sets ranged from 2 to 27. One
can see from Figure 4.1 that the sets often include metabolites of related metabolite
classes. For example six sets include carnitines exclusively. Diﬀerent forms of phos-
phatidylcholines were found to be in a set with each other or with sphingomyelins. 116
metabolites were part of at least one phenotype class, that means for 35 metabolites
there was no metabolite with a pairwise correlation higher than 0.3. A detailed list of
metabolites in each metabolite set is given in Appendix Table C.3.
The metabolite sets for Metabolon metabolites presented in Figure 4.2 were determined in
the same way. For this data 50 diﬀerent metabolite groups were identiﬁed (13 metabolite
sets were detected by both cutoﬀ values). The size of the metabolite sets ranged between
2 and 20. The metabolite sets for Metabolon metabolites also included often related
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Figure 4.1.: GGM-deﬁned Biocrates metabolite sets. Each metabolite of a set is
represented by a box coloured according to its metabolite class. The sets
that were identiﬁed with both partial correlation coeﬃcient (PPC) cutoﬀs
are marked with a star.
metabolites (see Figure 4.2). For example many sets contained only metabolites of lipid
pathways, two sets consisted of a combination of lipid and energy pathway metabolites
(detailed list of metabolites in each metabolite set is given in Appendix Table C.4). All in
all, 115 metabolites were part of at least one metabolite set. In the metabolite measure-
ments of the TwinsUK, which was used for replication, two of these 115 metabolites were
missing. Therefore, for the replication two metabolite sets had to be modiﬁed, as they
include at least one of these missing metabolites. One set was made up only from these
two metabolites and had to be excluded from the replication. The other set included
several other metabolites and could be tested in a modiﬁed form.
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Figure 4.2.: GGM-deﬁned Metabolon metabolite sets. Each metabolite of a set
is represented by a box coloured according to its metabolite super pathway.
The sets that were identiﬁed with both partial correlation coeﬃcient (PPC)
cutoﬀs are marked with a star.
Genotypic and Phenotypic input
For KORA F4 the same genotyping and imputation was used as described in section 3.1.
The genotyping of the replication cohort TwinsUK was performed with a combination
of diﬀerent Illumina arrays (HumanHap300, HumanHap510Q, 1M-Duo and 1.2MDuo
1M). For each set Illuminus calling algorithm was used (Duo arrays pooled for calling).
After sample and SNP-wise ﬁltering the data was pooled and imputed using Impute v2
(Marchini and Howie, 2010) (reference HapMap 2 and the combined HumanHap610k and
1M reduced to 610k SNP content). More details on genotyping were given in previous
publications (e.g. Soranzo et al., 2009; Suhre et al., 2011). The analysis was restricted
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to unrelated individuals. SNPs were ﬁltered for minor allele frequency higher than 5%,
call rate higher than 95% and imputation quality higher than 0.4.
For both Metabolon and Biocrates metabolites outliers that diﬀered more than ﬁve stan-
dard deviation from the mean were excluded. The residuals of log-transformed metabo-
lites with adjustment for sex and age were calculated and taken as phenotypic input for
PSEA. For Biocrates metabolites additional adjustment for an internal batch variable
accounting for possible measurement diﬀerences was applied. It could be seen that after
log-transformation most (146) Biocrates metabolites were closer to the normal distri-
bution than untransformed metabolite concentrations. For Metabolon metabolites the
same was previously shown with log10-transformation (Suhre et al., 2011). For simplicity
per panel the same transformation was applied to all metabolites.
For PSEA an approach was applied that increased the number of permutations stepwise.
It started with 100 permutations calculated for all genes. Genes, for which at least
one phenotype set was enriched with a p-value ≤ 0.03, were taken forward for the next
step of 1,000 permutations. In the third step, 10,000 permutations were performed for
genes with a p-value ≤ 0.003. The lowest possible p-value 10−4 was taken as signiﬁcance
level. Replication of all signiﬁcant enrichments was calculated in TwinsUK with 10,000
permutations (see Appendix Figure C.1).
4.2. PSEA Results on Biocrates Metabolites
PSEA on KORA F4 Biocrates metabolites found 35 phenotype sets signiﬁcantly enriched
for at least one gene (p-value ≤ 10−4). 163 genes were identiﬁed, which belonged to 61
diﬀerent gene groups. All in all, 354 phenotype set gene combinations were signiﬁcant
including 35 diﬀerent phenotype sets and 163 genes in 61 gene groups. The 163 genes
were taken forward for replication in TwinsUK data. After correction for 61 independent
gene groups, 129 of the 354 signiﬁcant enrichments were replicated (signiﬁcance level:
0.05/61 ≈ 0.00082). These 129 enrichments were identiﬁed at six diﬀerent gene groups.
The replicated results are presented in Table 4.1.
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Table 4.1.: Replicated PSEA results on GGM-deﬁned Biocrates metabolite
sets. For the presented genes the given phenotype sets showed an enrichment
with a p-value < 10−4 in PSEA on KORA F4 and a p-value < 8.2 · 10−4 on
TwinsUK data. Gene groups are separated with background colour.
start pos. stop pos. phenotype sets (set_*_b)
chr. 1 75852750 76280263 17
genes: ACADM, RABGGTB, SNORD45A, SNORD45B, SNORD45C, MSH4, ASB17
chr. 2 210942386 211291577 5
genes: CPS1
chr. 4 159702854 160087236 17
genes: ETFDH , C4orf46, FNIP2, PPID
chr. 10 61042363 61248406 1
genes: SLC16A9
chr. 11 61094821 61430694 11, 14, 23, 24, 30, 31, 32, 33, 35, 8
genes: C11orf9, FEN1, DKFZP434K028, DAGLA, FADS2,
chr. 11 61273486 61527475 11, 14, 23, 24, 30, 31, 32, 33, 35
genes: C11orf10, MIR611, FADS1, MIR1908, FADS3, BEST1
chr. 11 61381461 61551489 23, 24, 31, 35
genes: RAB3IL1
chr. 14 63189959 63799513 36
genes: SGPP1, SYNE2
chr. 14 66884273 67165389 16, 30
genes: PLEK2, PLEKHH1, TMEM229B
Enrichment of Amino Acid Sets
At the CPS1 gene an enrichment of the set_5_b was replicated. This set consisted of
three amino acids (glycine, serine and threonine).
Enrichment of Lipid Pathway Related Sets
Two non overlapping sets (set_16_b, set_30_b), which included both two acyl-alkyl-
phosphatidylcholines, were signiﬁcantly enriched for three genes (PLEK2, PLEKHH1,
TMEM229B) in a region on chromosome 14. On chromosome eleven there was a re-
gion including the FADS cluster (FADS1, FADS2, FADS3 ), in which diﬀerent phenotype
sets showed enrichment at twelve genes. These phenotype sets included diacyl-phospha-
tidylcholines, acyl-alkyl-phosphatidylcholines and lyso-phosphatidylcholines. Four sets
(set_*_b: 23, 24, 31, 35) were enriched for all twelve genes. For the other genes respec-
tively six (set_*_b: 11, 14, 30, 32, 33) or seven phenotype sets (additionally set_8_b)
were signiﬁcantly enriched and replicated. It could be observed that the identiﬁed sets
were overlapping especially with set_11_b and set_14_b, which were the largest sets
identiﬁed for Biocrates metabolites. At last the phenotype set set_36_b that consisted
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of two hydroxysphingomyelins (hydroxysphingomyelin C14:1 and C16:1) was found to be
enriched for SGPP1 and SYNE2 on chromosome 14.
Enrichment of Carnitine Sets
The phenotype set set_17_b, which included two acylcarnitines (decanoylcarnitine, oc-
tanoylcarnitine), was enriched and replicated for seven genes, including ACADM in a
gene group on the ﬁrst chromosome. The enrichment of the same phenotype set was
replicated for ETFDH and other genes of a gene group on chromosome four. Another
phenotype set (set_1_b) that consisted of free carnitine and propionylcarnitine was en-
riched and replicated for SLC16A9.
4.3. PSEA Results on Metabolon Metabolites
PSEA on Metabolon metabolite sets in KORA F4 revealed 344 signiﬁcant enrichments of
phenotype sets. 35 metabolite sets had at least one signiﬁcant enrichment. These enrich-
ments were located at 252 diﬀerent genes, which could be grouped into 58 independent
gene groups. In the replication step these 344 signiﬁcant enrichments were analyzed on
TwinsUK data. The replication signiﬁcance level was corrected for the 58 not overlapping
gene regions (replication signiﬁcance level: 0.05/58 = 8.6 · 10−4). 183 enrichments at 66
genes (8 gene groups) and 10 phenotype sets could be replicated in TwinsUK data. The
detailed results are presented in Table 4.2.
Results of Amino Acids Sets
A set of creatine and pyroglutamine (set_25_m) as well as a set of glycine and serine
(set_33_m) were enriched for CPS1. In a larger gene region on chromosome twelve
a set that consisted of a peptide (γ-glutamyl-glutamine) and a amino acid (glutamin)
(set_29_m) was enriched and replicated. Among others GLS2 was identiﬁed.
Results of Carbohydrate Sets
Only one metabolite set of the carbohydrate pathway was signiﬁcantly enriched and
replicated. At a region on chromosome two including GCKR and four other genes the
metabolite set of glucose and mannose (set_31_m) was enriched.
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Table 4.2.: Replicated PSEA results on GGM-deﬁned Metabolon metabolite
sets. For the presented genes the given phenotype sets showed an enrichment
with a p-value < 10−4 in PSEA on KORA F4 and a p-value < 8.6 · 10−4 on
TwinsUK data. Gene groups are separated with background colour.
start pos. stop pos. phenotype sets (set_*_m)
chr. 1 75402838 76907932 47, 9
genes: SLC44A5, ACADM, RABGGTB, SNORD45A, SNORD45B, SNORD45C, MSH4,
ASB17, ST6GALNAC3
chr. 2 27464973 27766306 31
genes: GCKR, FNDC4, C2orf16, ZNF512, GPN1
chr. 2 210942386 211291577 25, 33
genes: CPS1
chr. 2 234009939 234427219 20
genes: USP40, UGT1A8, UGT1A10, UGT1A9, UGT1A7, UGT1A6, UGT1A5, UGT1A4,
UGT1A3, UGT1A1, DNAJB3
chr. 4 159702854 159973810 47, 9
genes: ETFDH, C4orf46, PPID
chr. 4 159808181 160087236 9
genes: FNIP2
chr. 7 98700955 99508811 17
genes: ARPC1B, BUD31, CPSF4, PDAP1, ZNF789, PTCD1, ZKSCAN5, ATP5J2, ZNF655,
ZNF394, FAM200A, ZNF498 CYP3A5, CYP3A7, CYP3A4, CYP3A43, OR2AE1,
TRIM4, GJC3, ZKSCAN1
chr. 11 61166755 61430694 40, 41
genes: C11orf9, FEN1, DKFZP434K028, FADS2
chr. 11 61273486 61525549 40
genes: C11orf10, MIR611, FADS1, MIR1908, FADS3
chr. 12 54985890 55309551 29
genes: STAT2, APOF, SPRYD4, TIMELESS, MIP, RBMS2, GLS2
Results of Cofactors and Vitamins
On chromosome 10 there were several genes of the UGT1A UDP glucuronosyltransferase
1 family (and three other genes) that were identiﬁed for a signiﬁcant enrichment of
set_20_m consiting of bilirubin(E;E) and bilirubin(Z;Z).
Results of Carnitine Sets
Signiﬁcant enrichments of two phenotype sets (set_9_m and set_47_m) were replicated
for nine genes of one region on the ﬁrst chromosome including ACADM. The same set
was enriched and replicated for ETFDH and two other genes (region on chromosome
4). In the same region there was one gene (FNIP2 ) for which only the enrichment with
set_9_m could be replicated. The set set_47_m consisted of three carnitines: carnitine,
hexanoylcarnitine and octanoylcarnitine. These three metabolites were also elements of
set_9_m besides a fourth carnitine (2-tetradecenoyl carnitine).
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Results of Lipid Pathway Related Sets
In a region on chromosome seven several genes including CYP3A5 were found with
an enrichment of set_17_m that included two metabolites of the lipid/sterol/steroid
pathway (androsterone, epiandrosterone). The region including the FADS -cluster showed
enrichment with set_40_m and set_41_m or only with set_40_m. Both sets were not
overlapping and included diﬀerent glycerolipids, lysolipids or fatty acids.
4.4. Discussion of PSEA Results on Predeﬁned Phenotype
Sets
PSEA on metabolomics data with usage of the predeﬁned sets derived from the GGM
revealed several loci that showed enrichment with one or more metabolite sets. As some
metabolites were measured by both panels or closely related metabolites were covered,
it was not surprising that three gene regions were identiﬁed for both metabolite panels.
These gene regions include ACADM, CPS1 and several genes surrounding the FADS
cluster. Additionally, four gene regions were identiﬁed only with Biocrates data and ﬁve
with Metabolon data only.
The enriched phenotype sets carried valuable information on the underlying processes,
which can be seen exemplarily for the enrichment at ACADM :
The enriched sets for ACADM consisted of decanoylcarnitine and octanoylcarnitine for
Biocrates data and of carnitine, hexanoyl-, octanoyl- and 2-tetradecenoyl carnitine for
Metabolon data. The gene product of ACADM, the medium chain acyl-coenzyme A
dehydrogenase, catalyzes the ﬁrst step of β-oxidation. The medium chain acyl-coenzyme
A dehydrogenase supports the generation of the acyl-coenzyme A with carnitine from
medium chain acylcarnitine. Therefore acylcarnitines with medium chain length (4−12)
are known to be substrates of the gene product of ACADM (Nichols et al., 2008). This
biological connection was reﬂected in the results of PSEA.
In GWAS ACADM was found to be associated with concentrations of all phenotype
set elements except for carnitine and 2-tetradecenoyl carnitine but these were part of
37
4. Application to Metabolomics Data  Predeﬁned Phenotype Sets
signiﬁcantly associated ratios.
Further comparison of PSEA ﬁndings with GWAS results showed, that all identiﬁed
genetic loci were previously associated in single phenotype analyses on metabolite con-
centrations or ratios on the same data (Illig et al., 2010; Suhre et al., 2011). It could
be observed that the identiﬁed enriched phenotype sets corresponded to the published
single phenotype association. The gene function was discussed in the related publications
(Gieger et al., 2008; Illig et al., 2010; Suhre et al., 2011).
On the one hand, the application showed that PSEA is able to identify loci that are asso-
ciated with sets of metabolites. The phenotype sets that were enriched for a speciﬁc gene
carry information about the underlying processes as seen for the example of ACADM.
On the other hand, new genes could not be identiﬁed.
One reason for this could be that loci identiﬁed for metabolites often mirror the substrate
aﬃnity of the coded enzymes. Therefore, the strength of association is very high, e.g. in
GWAS on Biocrates metabolites p-values are observed in the size of 3.5 · 10−78 (C4,
ACADS ) for concentrations and in the size of 6.5 · 10−179 (PC.aa.C36.3/PC.aa.C.36.4,
FADS ) for ratios. On Metabolon metabolites the minimal p-values are even lower:
5.4 ·10−252 (N-acetylornithine, NAT8 ) for concentrations and < 4.4 ·10−305 (Butyrylcar-
nitine/propionylcarnitine, ACADS ) for ratios. Such stong associations could easily be
detected in single phenotype GWAS.
Another reason might be the determination of predeﬁned metabolite sets with GGM. It
could be observed that the GGM-deﬁned phenotype sets represent sensible and impor-
tant biological processes. This is conﬁrmed as the found enrichments were conform with
the GWAS results. But apparently, the hypotheses proposed by GGM did not led to new
identiﬁed loci. As any deﬁnition of phenotype sets lead to a limitation of hypotheses,
this is not a special problem of the usage of GGM. In fact the limitation is even necessary
to reduce the computing time of PSEA. One opportunity to enlarge the hypotheses in
addition to the predeﬁned phenotype sets is the internal identiﬁcation of new phenotype
sets, which is one extension of PSEA.
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Identiﬁcation of New Phenotype Sets
The internal identiﬁcation of new phenotype sets, made possible by the ﬁrst extension of
PSEA, expands the hypotheses of predeﬁned phenotype sets with promising new identi-
ﬁed sets. In this chapter the application of this extension on Biocrates and Metabolon
metabolite panels is presented. Selected results will be discussed biologically. Compar-
isons between the approach of predeﬁned phenotype sets and the internal new identiﬁca-
tion of phenotype sets are discussed, with respect to the potential of the latter to unravel
additional information.
5.1. Identiﬁcation of New Metabolite Sets
The extension of PSEA to detect new phenotype sets was used as described in section
2.2. All metabolites for which a gene had an association p-value lower than 5 · 10−4 were
grouped to a new phenotype set for this genes and analyzed for enrichment. The same
metabolites and genotypes of KORA F4 and TwinsUK with the same quality control
were used as described in section 4.1.
For a large number of genes new phenotype sets (11,607 Biocrates, 14,993 Metabolon)
were identiﬁed. As most of the new identiﬁed phenotype sets (shortly named: new pheno-
type sets) had a low p-value (≤ 0.003) after 1,000 permutations (10,850 Biocrates, 14,781
Metabolon), an intermediate replication step was performed, to reduce the computational
eﬀort. That means, all genes at which a phenotype set, newly identiﬁed in KORA F4,
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had a p-value ≤ 0.003 after 1,000 permutations were replicated in TwinsUK with 1,000
permutations. Only those genes at which a new phenotype set gained a p-value ≤ 0.003
in PSEA on TwinsUK with 1,000 permutations (intermediate replication) were analyzed
in KORA F4 with 10,000 permutations. For all signiﬁcant ﬁndings of PSEA in KORA
F4 with 10,000 permutations (p-value < 0.0001) replication in TwinsUK with 10,000 was
performed (see Appendix Figure D.1).
5.2. PSEA Results on Biocrates Metabolites
A number of 62 genes showed a signiﬁcant enrichment of new phenotype sets (p-value <
0.0001). These genes belonged to 22 independent gene groups. A signiﬁcant enrichment
of a phenotype set is counted only once per gene group even if a new phenotype set
was identiﬁed and signiﬁcantly enriched for several genes of a gene group. That led to
a number of 45 signiﬁcant enrichments. After correcting the replication p-value for 45
independent enrichments (0.05/45 ≈ 0.001), 46 ﬁndings could be replicated including 15
gene groups and 33 new phenotype sets. All new identiﬁed, signiﬁcantly enriched and
replicated sets are presented in Figure 5.1 and Appendix Table D.1.
In general, the new identiﬁed phenotypes sets were larger than the predeﬁned phenotype
sets. 15 of the signiﬁcantly enriched and replicated new metabolite sets included more
than 20 metabolites. In contrast to that, only one of the predeﬁned phenotype sets
included more than 20 metabolites. Moreover, one could observe that the new phenotype
sets included more metabolites of diﬀerent metabolite classes.
Six gene groups that were associated with a new set showed a signiﬁcant and replicated
enrichment with a predeﬁned set as well (see Figure 5.1). The new phenotype sets
for these genes included at least some elements of the enriched predeﬁned sets, but
often more metabolites than this. For example, the new set at ETFDH consisted of two
acylcarnitines (C8, C10) and one sphingomyelin (SM.C26.0). The predeﬁned set that was
enriched for ETFDH is a subset of these metabolites including the two acylcarnitines. A
more extreme example is the enrichment of SLC16A9. The new phenotype set included
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Figure 5.1.: New identiﬁed sets for Biocrates metabolites. All new metabolite sets
that were signiﬁcantly enriched in KORA F4 and replicated in TwinsUK are
presented along with the genes at which they were identiﬁed. Each metabo-
lite of a set is represented by a box coloured according to its metabolite class.
The brackets on the left side state if at least one gene of the gene group was
identiﬁed with PSEA for an enrichment of a GGM-deﬁned set on the same
data, with GWAS on the same data or if the locus is new. The genes that
were previously identiﬁed with the named analyses are printed in bold let-
ters. SLC22A1 was found in GWAS to be associated with one metabolite
of the Metabolon data but not with Biocrates, therefore it is marked with a
star.
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15 metabolites of eight diﬀerent metabolite classes. The predeﬁned phenotype set that
was signiﬁcantly enriched and replicated for this gene (C0, C3) is a subset of the new
phenotype set. Similar observations could be made for the gene region including CPS1.
The predeﬁned phenotype set enriched for CPS1 consisted of three amino acids. Besides
two of these amino acids, diﬀerent forms of carnitines and phosphatidylcholines were
included in the new phenotype sets. The largest signiﬁcantly enriched and replicated
new phenotype sets were identiﬁed at the FADS cluster. For FADS2 a phenotype set
of 58 metabolites was replicated. Lipid related metabolites made up the major fraction
of the identiﬁed sets at this gene group. At SYNE2/SGPP1 the identiﬁed phenotype
sets included one hydroxysphingomyelin, two phosphatidylcholines and at SYNE2 some
acylcarnitines. Only one hydroxyspingomyelin was part of both the new phenotype sets
and the signiﬁcantly enriched predeﬁned phenotype sets at these genes.
The remaining nine gene groups were not found with PSEA on predeﬁned metabolite sets
neither on Biocrates nor on Metabolon data. These gene groups include the additional
information gained with internal identiﬁcation of new phenotype sets with PSEA.
5.3. PSEA Results on Metabolon Metabolites
242 genes of 63 independent gene groups were identiﬁed to have a signiﬁcant enrichment
with a new phenotype set in KORA F4. 39 of these signiﬁcant ﬁndings (19 phenotype
sets) could not be analyzed for replication as less than two metabolites of each set were
available in TwinsUK data (results presented in Appendix Table D.3). The signiﬁcance
level of the replication step had to be corrected for the number of signiﬁcant ﬁndings.
Each new phenotype set in the remaining 203 signiﬁcant enrichments was counted only
once per gene group. These led to a number of 107 signiﬁcant enrichments. With this
correction (0.05/107 ≈ 0.0005) 131 enrichments could be replicated in TwinsUK data.
This included 67 diﬀerent phenotype sets and 131 genes at 23 gene groups. The results
are presented in Figure 5.2 and in Appendix Table D.2.
Same observations concerning size and diversity of the new phenotype sets could be made
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as described above for new sets on Biocrates data.
Several genes of seven gene groups were signiﬁcantly enriched and replicated with pre-
deﬁned phenotype sets (indicated in Figure 5.2). At some gene groups the metabolites
of the new phenotype sets belonged to the same metabolite classes as the metabolites
of the GGM-deﬁned sets. For example the new phenotype sets of GLS2, MIP, TIME-
LESS, APOF and SPRYD4 included the amino acid and peptide of the predeﬁned set
besides additional amino acids and nucleotides. For the gene group including the FADS
gene, which showed enrichment for predeﬁned sets of metabolites related to the lipid
metabolism, the new phenotype sets were observed to include mainly metabolites of
the lipid metabolism as well. The same was true for genes of a gene region including
CYP3A4. For the other four gene groups, that showed signiﬁcant enrichment with pre-
deﬁned and new phenotype sets, the new phenotype sets included metabolites of more
diverse pathways. At ACADM and surrounding genes several carnitines were included in
Figure 5.2. (on the next page): New identiﬁed sets for Metabolon metabolites.
All new identiﬁed metabolite sets that were signiﬁcantly
enriched in KORA F4 and replicated in TwinsUK are
presented along with the genes at which they were iden-
tiﬁed. Each metabolite of a set is represented by a box
coloured according to its superpathway. Not overlapping
gene groups are separated with horizontal spaces. The
brackets on the left side state if at least one gene of the
gene group was identiﬁed with PSEA on a GGM-deﬁned
set on the same data, with GWAS on the same data or if
the locus is new. The genes that were previously identi-
ﬁed with the named analyses are printed in bold letters.
If not the gene which is presented here but another gene
of the gene group was previously identiﬁed, the known
gene is given in brackets.
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the new phenotype sets. This corresponds to the enriched predeﬁned phenotype sets at
this gene group. But apart from that also some fatty acids and metabolites of the amino
acid super pathway were part of the new phenotype sets. Genes at the gene region of
GCKR were identiﬁed with the predeﬁned phenotype set of glucose and mannose. The
new phenotype sets at these gene included up to 17 diﬀerent metabolites. They consisted
of the carbohydrates lactate, mannose and threitol (nucleotide sugar) but also various
metabolites of the glycerolipid metabolism and amino acids of the glutamate metabolism.
Both predeﬁned phenotype sets that were signiﬁcantly enriched for CPS1 included two
amino acids. These four amino acids were part of the new phenotype sets at CPS1 along
with two more amino acids, two fatty acids and the amino sugar erythronate. For the
region around the UGT1A gene the new phenotype sets included, in addition to the
two isomers of billirubin that made up the predeﬁned set, some metabolites of the lipid
and amino acid metabolism. The remaining 16 gene groups were new, as they were not
identiﬁed with any predeﬁned phenotype set.
5.4. Discussion of the PSEA Results on New Identiﬁed
Phenotype Sets
PSEA with the extension for identiﬁcation of new phenotype sets identiﬁed on Biocrates
data 15 gene groups and on Metabolon data 23 gene groups, that showed enrichment
of a new metabolite set. As mentioned above, six respectively seven gene groups were
found in the analysis of predeﬁned phenotype sets as well. The comparison with GWAS
on the same data revealed that additional three gene groups of the Biocrates results and
nine gene groups of the Metabolon results are signiﬁcantly associated with at least one
metabolite concentration or ratio (Illig et al., 2010; Suhre et al., 2011) (see Figures 5.1
and 5.2). One of the new loci (SLC22A1 ) identiﬁed on Biocrates data was found with a
signiﬁcant association in GWAS on Metabolon data. In total, ﬁve new loci on Biocrates
data and seven on Metabolon data were not found in the GWAS on the metabolite data
sets. The elements of the identiﬁed and enriched metabolite sets enabled insight into the
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underlying processes of genes, their products and various metabolites. Three genetic loci
that are not associated in a single phenotype GWAS on the metabolite data but were
found with PSEA are discussed here exemplarily. The remaining nine new genetic loci
are discussed in the Appendix section D.2. Interpretation of genes known from GWAS
can be found in the corresponding publications (Illig et al., 2010; Suhre et al., 2011).
IL3 : A set of six acylcarnitines, one dicarboxyacylcarnitine, one acyl-alkyl-phosphatidyl-
choline and one hydroxysphingomyelin was enriched for interleukin 3 (IL3 ) on Biocrates
metabolites. IL3 is known to be a hematopoietic growth factor that stimulates survival,
multiplication and diﬀerentiation of hematopoietic cells (Lopez et al., 1988). Other stud-
ies found that IL3 stimulates the phospholipid synthesis (Bauer et al., 2005) and sup-
presses lipid degradation and β-oxidation of fatty acids (Deberardinis et al., 2006). This
eﬀect supports the function of IL3 as hematopoietic growth factor as lipid synthesis is
required for proliferation of various cell types (Kuhajda et al., 1994; Deberardinis et al.,
2006). In β-oxidation of lipids, e.g. phosphatidylcholines, acylcarnitines are needed for
the transport of lipids into the mitochondria. Therefore, the elements of the enriched
phenotype set represent the eﬀect of IL3 on the lipid synthesis. Additionally, a recent
study showed that there might be a protective eﬀect of a SNP in IL3 against malaria
attacks (Meyer et al., 2011). GWAS found this gene to be genome wide signiﬁcantly
associated with Chron's disease (Franke et al., 2010).
cytochrome P450 family 4: Four genes of the cytochrome P450 family 4 (CYP4B1,
CYP4A11, CYP4X1, CYP4Z2P) and one additional gene KIAA0494 that is overlapping
with CYP4B1 were found on Metabolon metabolites with an enrichment of four slightly
diﬀerent new metabolite sets. The sets included three to six metabolites. Two glyc-
erolipids were part of several sets as well as one fatty acid and two carnitines. The amino
acid L-tyrosine and the peptide γ-glutamyltyrosine were part of two enriched new phe-
notype sets. Also the cofactor heme was identiﬁed for two genes. The cytochrome P450
monooxygenase system (CYP) is a multigene superfamily of enzymes that are involved
in various reactions e.g. drug metabolism and synthesis of lipids. Heme is a cofactor in
these processes (Chaudhary et al., 2009). The metabolites identiﬁed as elements of the
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metabolite sets seem to reﬂect the gene product's function. The glycerolipids and the
fatty acid might be substrates of the gene products. As stated, heme is a cofactor of the
cytochrome P450 enzymes. Carnitines are known to play a role in fatty acid metabolism.
Additionally, the gene CYP4A11 was found to be associated with hypertension (Gainer
et al., 2005).
LINGO2 : A large set of 17 Metabolon metabolites was identiﬁed and signiﬁcantly
enriched at the gene LINGO2. The set included various types of metabolites of the
lipid metabolism (fatty acids, carnitines, lysolipid, monoacylglycerol), some amino acids,
one nucleotide, one peptide (Fibrinogen cleavage peptide) and phenylsulfate. The gene
function of leucine rich repeat and Ig domain containing 2 (LINGO2 ) is not known yet. A
GWAS identiﬁed a genome wide signiﬁcant association of LINOG2 with BMI (Speliotes
et al., 2010). Moreover, it was reported to be associated with Parkinson's disease (Wu
et al., 2011). The elements of the enriched metabolite set possibly hint to an involvement
in the metabolism of fatty acids. This could explain the eﬀect on BMI.
These results demonstrated how the identiﬁcation of new phenotype sets in PSEA im-
prove the knowledge on genes and their function. For IL3 the elements of the phenotype
set are substrates of one gene product's function. Similar observations could be made
for the cytochrome P450 family. The elements of the enriched phenotype sets seem to
reﬂect substrates of the processes in which the gene products are involved. As special
aspect also heme, which is a known cofactor for these reactions, was identiﬁed in the new
phenotype set. For these two examples, the ﬁndings of PSEA on metabolites supported
the known gene functions. In the third example, the enriched phenotype set provided an
possibly informative basis for the gene function of LINGO2, which is not known yet.
The internal identiﬁcation of new phenotype sets of PSEA enlarged the approach of
testing predeﬁned phenotype sets with valuable hypotheses. One example is the gene
ACADS. It is known to be strongly associated with medium chain length acyl-carnitines.
None of the GGM-deﬁned phenotype set consisted of medium chain length acyl-carnitines
and therefore it could not be found with the predeﬁned metabolite sets. But the results of
the internal identiﬁcation of new phenotype sets in PSEA showed an enrichment of a new
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phenotype set including medium chain acylcarnitines. The enrichment could be observed
for both metabolite panels. This example demonstrates how the internal identiﬁcation of
phenotype sets can help to overcome the limitation given by the selection of predeﬁned
phenotype sets.
Most loci but not all that were found with an enrichment of a GGM-deﬁned set also
showed an enrichment with a new set. In other words the internal identiﬁcation of new
phenotype sets did not reproduce all enrichments that were found with the predeﬁned
phenotype sets. One reason for this is that the GGM-deﬁned phenotype sets could
test phenotypes in a more speciﬁc way as the internal identiﬁcation of new phenotype
sets. It was observed that the new phenotype sets were larger and included more often
metabolites of diﬀerent metabolite classes as in the GGM-deﬁned metabolite sets. This
diversity could be caused by spurious association of metabolites due to the ﬁxed p-value
criterion in the identiﬁcation of phenotype sets. Sets including many spurious associated
metabolites would very likely not pass the replication. Due to this some genes might
not be identiﬁed with an enrichment of a new phenotype set. Therefore, the internal
identiﬁcation of new phenotype sets could not replace the analysis of predeﬁned loci but
expand it.
The analysis of new phenotype sets found additional genetic loci that have eﬀect on
metabolite sets. Moreover, it was demonstrated that it improved the knowledge on the
underlying relations of genes and metabolites and helped to get a more detailed picture of
the gene function. Therefore, the extension of PSEA enlarged the possibilities of PSEA.
Both testing predeﬁned phenotype sets and identiﬁcation of new phenotype sets, have
special advantages, a combination of both would lead to best results.
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In the discussion parts of the previous chapters 2-5 speciﬁc aspects of PSEA and its
applications were discussed. This chapter outlines a more general consideration of the
algorithm. Apart from the evaluation of general abilities and limitations, possible analysis
strategies including PSEA are presented. At last an overall conclusion is given.
Abilities and Limitations of PSEA
In the introduction two aims of gene based multiple phenotype analysis were named:
First the understanding of shared genetic basis of diﬀerent phenotypes and second the
identiﬁcation of new associated genes. The presented applications of PSEA have demon-
strated that PSEA satisﬁes both objectives. Each signiﬁcant enrichment of a phenotype
set carries information about the common genetic basis of the phenotypes in the set.
For example the enrichment of diﬀerent sets of amino acids in Biocrates and Metabolon
data at CPS1, as reported in chapter 4, enabled the conclusion of CPS1 being involved
in a shared pathway of these amino acids. Findings in terms of the second aim could
be observed for the application to iron and blood count traits in KORA described in
chapter 3. PSEA identiﬁed new loci associated with various phenotype sets. Some of
them were new as they were not genome wide signiﬁcant in a single phenotype analysis
on the same data. This demonstrated the ability of PSEA to identify more loci that
have an eﬀect on multiple phenotypes than single phenotype GWAS. The phenotype sets
that were enriched at these loci consisted of correlated phenotypes. PSEA exploited this
correlation structure, which led to the successful identiﬁcation of additional loci. The
applied permutation test prevented overestimation caused by dependency of phenotypes.
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The usage of phenotype sets has several beneﬁts for the analysis of multiple phenotypes.
Phenotype sets can be deﬁned easily. Prior knowledge on phenotypes can be integrated,
but it is not necessary to have detailed information about their interdependency. Alter-
native hypotheses can be integrated with diﬀerent phenotype sets. Phenotype sets might
overlap or be a subset of another phenotype set. A single PSEA run can test several
diﬀerent sets in parallel. Another advantage is the ability to deal with many phenotypes
and large phenotype sets, which was demonstrated with the successful application to
metabolomics data presented in chapter 4 and 5.
Self-evident, the ﬁndings of PSEA are highly dependent of the analyzed predeﬁned phe-
notype sets. In the applications described in chapter 3 and 4, two diﬀerent approaches
were used to determine predeﬁned phenotype sets: the use of prior knowledge in the
application to iron and blood count related phenotypes and a data driven strategy with
the GGM for the metabolite data sets. The focus of PSEA is to test given sets for en-
richment. Therefore, PSEA does not test all possible multiple phenotype combinations.
Such a strategy would make the algorithm slower and not applicable to large phenotype
sets. Dependent on the situation one can integrate all possible phenotype combinations
as predeﬁned sets and force PSEA to test these. But in most situations only selected
phenotype sets would be of interest.
The strategy of analyzing predeﬁned phenotype sets is hypotheses testing. The described
extension of PSEA that allows the identiﬁcation of new phenotype sets opens PSEA to
be a hypotheses generating application.
For both applications additional signiﬁcant enrichments were found with this extension.
Especially for the application to the metabolites presented in chapter 5 it could be seen
that the new identiﬁed phenotype sets enabled the identiﬁcation of new genetic loci. One
issue of the ﬁxed p-value criterion for identiﬁcation of phenotype sets is, that it does not
account for the number of phenotypes under consideration. Therefore, more phenotypes
lead to more new phenotype sets, in other words a higher false positive rate among the
phenotype sets. In the applications one could observe that for the 14 iron and blood
phenotypes much fewer sets (296) were identiﬁed as for the metabolite panels (> 10,000
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each). Apart from the number of phenotypes the strength of association, which was
higher for metabolites, was a second reason for the higher number of new phenotype
sets on metabolite data. As mentioned above a data driven approach that accounts
for number and correlation of phenotypes might improve the results and be a point for
further development. But as demonstrated, the ﬁxed p-value selection criterion together
with a replication step led to valuable ﬁndings that would have been missed if only the
predeﬁned sets were analyzed.
It has been discussed above, the usage of GWAS summary statistics in PSEA, as en-
abled by the second extension, had some limitations. It was seen that the results were
dependent on the distribution of single phenotype association test statistics and the LD
structure. Even if PSEA on individual level genotypes and phenotypes is favourable, this
extension enlarges the applicability of PSEA to situations were individual level genotypes
and phenotypes are not available.
PSEA and Analysis Strategies
In this thesis two diﬀerent situation were presented, for which PSEA was successfully
applied. In general, two main kinds of applications could be deﬁned: First, using PSEA as
a screening tool for analyzing various phenotype set to get an idea of hidden genetic eﬀects
on multiple phenotypes. Second, using PSEA for testing speciﬁc phenotype sets based
on prior knowledge for genetic eﬀects. Also a mixed form of both types is possible. Using
PSEA as screening tool is interesting for example if multiple correlated phenotypes are
available. For example in case single phenotype GWAS might reveal shared associations
that are not genome wide signiﬁcant, testing eﬀects on multiple phenotypes with PSEA
on a genome wide scale can lead to additional results. In such situations phenotype sets
might be deﬁned by correlation or p-value criteria. If one has access to single phenotype
GWAS or meta-analysis results but not to individual level genotypes, the extension
of PSEA on GWAS results enable the screening for multiple eﬀects without additional
analyses on the individual level data. In other cases biological insight can give hypotheses
for testing phenotype sets for enrichment in a gene region or on genome wide scale. Often
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the identiﬁcation of a shared genetic basis is the ﬁrst interest in such situations, but it
might also lead to identiﬁcation of new loci.
To integrate PSEA in an analysis pipeline, on has to distinguish between preparatory
analyses and (optional) subsequent analyses based on PSEA results. As stated above,
the most important preparation for PSEA is the deﬁnition of phenotype sets. In addition
to the mentioned approaches, network reconstruction methods or phenotype clustering
could be helpful for the deﬁnition of phenotype sets. Furthermore, the usage of infor-
mation on biological relations, e.g. from previous experiments or databases, might be a
good source of prior knowledge.
PSEA analyzes if there is any connection between one gene and a set of multiple phe-
notypes. Subsequent analyses can use the results of PSEA for further investigation. In
other words, the screening that is provided by PSEA points to the genetic associations
and phenotype sets that are worth an in-deep analyses. Methods that investigate the
relation of phenotype sets can be applied subsequently.
Further Development of PSEA
The algorithm of PSEA could be extended to other types of phenotypic input. For ex-
ample, the usage of binary phenotypes could be integrated with the usage of an logistic
regression instead of the linear regression. With the appropriate modiﬁcations of the
association test PSEA could also be transferred to analysis of related individuals. More-
over, changes in the gene based strategy are thinkable. As mentioned above, a slight
modiﬁcation would change the gene based approach of PSEA to a SNP based algorithm.
Even more easily, other deﬁnition of genes or genetic loci could be used for PSEA.
PSEA and Pleiotropy
Up to now the term pleiotropy was consciously not mentioned in context with PSEA.
Pleiotropy is usually deﬁned as one gene having eﬀects on diﬀerent independent traits
(Sivakumaran et al., 2011). On the contrary, the phenotype sets analyzed by PSEA
consist not necessarily of independent phenotypes. PSEA uses the correlation structure
of phenotypes in the phenotype sets to identify additionally loci. This was demonstrated
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in the analysis of highly correlated sets of iron phenotypes described in the third chapter.
The strategy of the permutation test prevents overestimation of eﬀects on correlated
phenotypes, as the correlation structure is conserved in the permutated phenotypes.
If the phenotype sets are made up of independent phenotypes, PSEA will investigate
pleiotropic eﬀects on these phenotypes. Therefore, on the one hand PSEA can be used
for the analysis of pleiotropic eﬀects, but on the other hand is not limited to this.
Conclusion
Genetic tests become more and more popular in the health care system and in direct-to-
customer services. Therefore, it is increasingly important to unravel shared genetic eﬀects
on diﬀerent traits. Hidden association may contain important information on the relation
and development of disease. PSEA was demonstrated to improve our understanding of
the genetic connection of phenotypes and to identify new loci. Moreover, it enables
both testing of hypotheses by the usage of prior knowledge in predeﬁned phenotype sets
and generation of new hypotheses with identiﬁcation of new sets. It is easy to apply
and can be generalized for other questions. Therefore, PSEA is a valuable tool for the
understanding of shared genetic basis of phenotypes and diseases. It can help to improve
the interpretation of genetic tests, our understanding of diseases and possibilities of
therapy development.
53
A. Supplementary Information: Methods
A.1. Permutation Strategy of PSEA
For a setting with N individuals and a phenotype set of M phenotypes let P be the
matrix of all phenotypes in the set.
P =

p1,1 · · · p1,M
p2,1 · · · p2,M
...
. . .
...
pN,1 · · · pN,M
 (A.1)
Let i ∈ {1, . . . , N} and m ∈ {1, . . . ,M}. pi,m is the value of the phenotype m for the
person i. The vector pi,· = (pi,1, pi,2, . . . , pi,M ) denotes the values of all phenotypes in
the phenotype set for the person i.
In the permutation these phenotype vectors are permuted over all individuals. With this
the phenotype values of a person stay together in the permutations, only the asignment to
the individuals is modiﬁed. In other words the permutation is performed by interchanging
the rows of the matrix P . For a permutation j = (j1, j2, ...jN ) of the vector (1, 2, . . . , N)
the matrix of permuted phenotypes is:
P (j) =

pj1,1 · · · pj1,M
pj2,1 · · · pj2,M
...
. . .
...
pjN ,1 · · · pjN ,M
 (A.2)
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In mathematical terms this permutation is equivalent to multiplication of the permutation
matrix Π(j) = {ej1 , . . . , ejN } with ejk , the jkth unit vektor and k ∈ {1, . . . , N}, to the
left side of the phenotype matrix P :
P (j) = Π(j) · P. (A.3)
This permutation scheme uses only the phenotypes of the phenotype set. Therefore, it
can be called self-contained in contrast to approaches that include also other phenotypes
than those of the phenotype set under consideration.
A.2. Estimation with FDR and FWER
The ESs for diﬀerent phenotype sets were not comparable as the phenotype sets diﬀered
in number of phenotypes and correlation between the phenotypes. Moreover, larger genes
were more likely to have a high gene based statistic by chance than smaller genes, since
larger genes include a higher number of SNPs. The ES can be made comparable by
standardization with mean and standard deviation of all permutation based ES. The
NES was calculated as
NES(PS, gene) =
ES (PS, gene)−meanj
(
ES(j) (PS, gene)
)
sdj
(
ES(j) (PS, gene)
) . (A.4)
This standardization method was used in various gene set enrichment approaches (Guo
et al., 2009; Wang et al., 2007). Replacing ES in the numerator of equation (A.4)
by a permutation based ES (ES(j)(PS, gene)) resulted in the permutation based NES
(NES(j)(PS, gene)).
With this the FDR and FWER can be used for estimation of enrichment.
False discovery rate (FDR): The FDR controls the fraction of false positive ﬁndings
(Benjamini and Hochberg, 1995). According to the FDR used by Wang et al. (2007),
the FDR for a phenotype set (PS*) and a gene (gene*) taking into account all other
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phenotype sets and genes was
FDR (PS∗, gene∗) =
#k,j,i
[
NES (PS∗, gene∗) ≤ NES(j) (PSk, genei)
]
#k,i [NES (PS∗, gene∗) ≤ NES (PSk, genei)]×Nperm . (A.5)
Thereby, the index j indicates the permutation (1 ≤ j ≤ Nperm), index i the gene
(1 ≤ i ≤ Ngene) and index k the phenotype set (1 ≤ k ≤ Npset).
Family wise error rate (FWER): The FWER is a highly conservative correction
procedure (Benjamini and Hochberg, 1995). It refers to the probability that the results
contain one or more false positive results. We transferred the FWER application of Wang
et al. (2007) in gene set enrichment to the situation of PSEA:
FWER (PS∗, gene∗) =
#j
[
NES (PS∗, gene∗) ≤ maxk,i
(
NES(j) (PSk, genei)
)]
Nperm
.
(A.6)
Thereby, the index j indicates the permutation (1 ≤ j ≤ Nperm), index i the gene
(1 ≤ i ≤ Ngene) and index k the phenotype set (1 ≤ k ≤ Npset).
A.3. Level and Power of the PSEA test
Level
Several publications discuss the problem of inﬂated α error rate in permutation tests
(Huang et al., 2006; Kaizar et al., 2011). They describe permutation tests in the situation
of a mean comparison with diﬀerent distributions of characteristics in the groups, which
can lead to an inﬂation of the α error rate. In the presented application of PSEA the
eﬀect of a SNP is assumed to be additive, which is the standard model in genome wide
association analyses. With this, the genotype could be treated as continuous variable.
Therefore, we think that this model avoids problems as mentioned above. A more detailed
discussion of suchlike issues might be needed if PSEA is generalized to other genetic
models.
Another point that should be mentioned in this context is the eﬀect of a limited number
of permutations. As discussed in chapter 2 due to the limited number of permutations it
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is not always possible to apply Bonferroni correction and this could lead to an increased
risk of false positive ﬁndings. As it is not always feasible to increase the number of
permutations, it was stated that a replication in an independent cohort should be per-
formed. The presented applications demonstrated that PSEA identiﬁed enrichments of
phenotype sets at genes that could be replicated.
Power
The theoretical determination of the power of PSEA is not feasible, as the testing pro-
cedure is very complex. A simulation based determination of power would also mean ex-
tensive analyses as there are many variable parameters that aﬀect the performance. The
most important parameters are: The mapping of SNPs to genes (number, LD structure),
as well as the association of SNPs and the number of phenotypes and their correlation
structure. General conclusions that consider all aspects could therefore only be gained
with extensive simulations.
Instead of a theoretical discussion of power it was demonstrated in the presented appli-
cations (chapter 3, 4 and 5) that the PSEA algorithm is able to detect interesting asso-
ciations that could be replicated in independent cohorts. Moreover, several phenotype
sets were found to be enriched at genes that are biologically related to the phenotypes.
Those ﬁndings were not only replicated, but biological plausible.
In chapter 3 the ﬁndings of PSEA were compared with results of single phenotype GWAS,
which is the state-of-the-art procedure for analysing associations of SNPs and (single)
phenotypes. It was exemplarily demonstrated that some genes could be identiﬁed with
PSEA for an enrichment of a phenotype set, but all single phenotype associations of the
set elements at this gene had a p-value above the genome wide signiﬁcance level. As the
genes were also found and replicated in independent large meta-analyses, they are likely
no false positives. Therefore, it was concluded that the power of PSEA for these genes
was higher than the single GWAS approach. Of course this is only one example and
therefore of limited information, but nevertheless it demonstrated the ability of PSEA
to detect other genes than single phenotype GWAS do.
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Iron Phenotypes
Table B.1.: Information about blood and iron phenotypes measurements in
KORA F3 and KORA F4.
phenotype unit
method
KORA F3 KORA F4
Iron µmol/l Colorimetric assay, (Cobas cr, Roche)
Ferritin ng/ml Electrochemiluminescence immunoassay (ECLIA)
stfr mg/l Tina-quant cr immunoturbidometry (Roche)
Transferrin g/l Immunonephelometry, (Behring Nephelometer cr, Siemens)
Ferritin ng/ml electrochemiluminescence immunoassay (Roche)
Transferrin saturation µmol/g 3.98 * Serum-Fe [µmol/l] / Transferrin [g/l]
HCT l/l Beckman Coulter STKS Beckman Coulter LH750
HGB g/l Beckman Coulter STKS Beckman Coulter LH750
MCH pg Beckman Coulter STKS Beckman Coulter LH750
MCHC g/l Beckman Coulter STKS Beckman Coulter LH750
MCV fl Beckman Coulter STKS Beckman Coulter LH750
RBC /pl Beckman Coulter STKS Beckman Coulter LH750
MPV fl Beckman Coulter STKS Beckman Coulter LH750
PLT /nl Beckman Coulter STKS Beckman Coulter LH750
WBC /nl Beckman Coulter STKS Beckman Coulter LH750
stfr: soluble transferrin receptor
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Table B.2.: Population statistics of blood and iron phenotypes. All characteristics
were calculated after exclusion of extreme phenotype values (±3 standard
deviations from mean). Units of phenotypes as speciﬁed in Table B.1. (N:
absolute number of individuals, min: minimal measurement, max: maximal
measurement, sd: standard deviation).
phenotype
KORA F3 KORA F4
N min max mean sd N min max mean sd
Iron 1625 2.3 32.8 16.67 5.12 1790 3.6 41.4 20.9 6.27
Ferritin 1610 3.9 829.5 199.04 162.56 1770 2.51 849.8 184.51 147.78
stfr 1620 1.12 5.57 2.67 0.72 1790 1.15 6.86 2.95 0.75
Transferrin 1622 1.55 3.56 2.50 0.33 1794 1.54 3.597 2.53 0.34
Transferrin saturation 1624 2.87 54.70 26.81 8.73 1788 4.21 69.32 33.38 10.82
HCT 1633 0.32 0.52 0.42 0.03 1803 0.32 0.51 0.41 0.03
HGB 1631 106 176 141.81 11.44 1805 106 176 141.10 11.53
MCH 1620 26.2 35.8 30.89 1.44 1787 26.3 36.1 31.2 1.53
MCHC 1633 317 357 337.06 6.78 1807 319 363 341.04 7.27
MCV 1625 79.4 104.1 91.55 3.79 1792 78.6 104.1 91.44 4
RBC 1635 3.41 5.73 4.6 0.39 1801 3.4 5.67 4.53 0.37
MPV 1600 6.4 11.4 8.67 0.91 1791 6.4 11.7 8.86 0.89
PLT 1625 75 421 243.76 54.04 1796 75 433 250.81 57.22
WBC 1639 3.2 13.4 6.78 1.66 1790 2.7 10.8 5.82 1.46
stfr: soluble transferrin receptor
Table B.3.: Published genes with known association with iron and/or blood
traits. The presented information was extracted from the corresponding
publications ([Benyamin, et al. 2009; Chambers, et al. 2009; Kullo, et al.
2010; Oexle, et al. 2011; Soranzo, et al. 2009; Tanaka, et al. 2010]). In the
last column all genes are speciﬁed to which the published SNP was be mapped
using the deﬁnition of gene regions (110 kb upstream, 40 kb downstream).
SNP trait gene p-value N publication other genes that in-
clude the published
SNP
rs10914144 MPV DNM3 2.10E-14 13943 Soranzo et al. (2009) DNM3
rs11065987 PLT ATXN2 2.20E-13 13943 Soranzo et al. (2009) ACAD10, ATXN2,
BRAP
rs11066301 PLT PTPN11 7.70E-12 13943 Soranzo et al. (2009) RPL6, PTPN11,
C12orf51
rs11071720 MPV TPM1 1.90E-08 13943 Soranzo et al. (2009) TPM1, LACTB
rs11602954 MPV BET1L 1.30E-14 13943 Soranzo et al. (2009) ATHL1, ODF3,
IFITM2,
LOC100133161,
BET1L, SCGB1C1,
SIRT3, RIC8A,
PSMD13, NLRP6
rs11970772 MCV BYSL,
CCND3
7.00E-19 13943 Soranzo et al. (2009) TAF8, CCND3, BYSL,
USP49, MED20
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rs12485738 MPV ARHGEF3 5.50E-31 13943 Soranzo et al. (2009) ARHGEF3
rs1668873 MPV TMCC2 1.40E-20 13943 Soranzo et al. (2009) DSTYK, NUAK2,
TMCC2
rs17342717 MCH SLC17A1 4.66E-08 3012 Kullo et al. (2010) SLC17A3,
HIST1H2AA,
SLC17A1
rs17609240 WBC GSDMA,
OR-
MDL3
4.66E-08 13943 Soranzo et al. (2009) IKZF3, GSDMA,
SNORD124, THRA,
ORMDL3, GSDMB,
PSMD3, CSF3
rs1800562 MCV HFE 1.40E-23 13943 Soranzo et al. (2009) HIST1H2BF,
HIST1H1T,
HIST1H2BC,
HIST1H2BB,
HIST1H2BE,
HIST1H2BD,
HIST1H1C,
HFE, HIST1H1E,
HIST1H2AC,
HIST1H1A,
HIST1H2AB,
HIST1H4C,
HIST1H4B,
HIST1H3B
stfr 1.17E-09 6616 Oexle et al. (2011)
MCH 2.76E-09 3012 Kullo et al. (2010)
transferrin 1.10E-10 459 Benyamin et al. (2009)
trans.
sat.
1.50E-15 459 Benyamin et al. (2009)
iron 3.50E-11 459 Benyamin et al. (2009)
rs210135 PLT BAK1 3.70E-10 13943 Soranzo et al. (2009) ITPR3, GGNBP1,
BAK1, C6orf227
rs2138852 MPV TAOK1 1.40E-23 13943 Soranzo et al. (2009) NUFIP2, TAOK1
rs236918 stfr PCSK7 1.41E-27 6616 Oexle et al. (2011) SIDT2, CEP164,
RNF214, PCSK7,
TAGLN
rs2393967 MPV JMJD1C 3.30E-21 13943 Soranzo et al. (2009) MIR1296, LOC84989,
JMJD1C
rs342293 MPV PIK3CG 1.60E-33 13943 Soranzo et al. (2009) FLJ36031
rs3811647 transferrin TF 3.00E-15 459 Benyamin et al. (2009) SRPRB, TOPBP1, TF
rs385893 PLT AK3 8.50E-17 13943 Soranzo et al. (2009) AK3, MIR101-2,
RCL1, C9orf68
rs4895441 RBC HBS1L 3.12E-14 3012 Kullo et al. (2010) HBS1L, MYB
MCH MYB 5.03E-13 3012 Kullo et al. (2010)
MCV 2.46E-13 3012 Kullo et al. (2010)
rs6136489 MPV SIRPA 7.70E-11 13943 Soranzo et al. (2009) SIRPA, PDYN
rs647316 MPV EHD3 3.20E-11 13943 Soranzo et al. (2009) CAPN14, GALNT14,
EHD3
rs7385804 RBC TFR2 4.90E-10 13943 Soranzo et al. (2009) PCOLCE, FBXO24,
POP7, GNB2, ZAN,
SAP25, MOSPD3,
ACTL6B, LRCH4,
EPO, TFR2
rs7961894 mpv WDR66 2.70E-44 13943 Soranzo et al. (2009) HPD, PSMD9,
WDR66, BCL7A
rs855791 mchc TMPRSS6 1.10E-12 3012 Kullo et al. (2010)
C22orf33, TST, TM-
PRSS6, KCTD17,
MPST
stfr 1.69E-15 6616 Oexle et al. (2011)
mcv 5.41E-09 3012 Kullo et al. (2010)
hgb 1.60E-13 16001 Chambers et al. (2009)
rs4820268 iron TMPRSS6 5.12E-09 2488 Kullo et al. (2010) C22orf33, TST,
KCTD17, TMPRSS6mch 2.41E-11 3012 Kullo et al. (2010)
rs893001 mpv CD226 1.40E-10 13943 Soranzo et al. (2009) CD226, DOK6
rs9609565 mcv FBXO7 4.30E-10 13943 Soranzo et al. (2009) BPIL2, C22orf28,
FBXO7, RFPL3S
stfr: soluble transferrin receptor, trans. sat.: transferrin saturation
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Table B.4.: Number of genes that were identiﬁed by PSEA on pruned and not
pruned SNPs. The table compares the number of genes identiﬁed with
PSEA based on pruned and not pruned SNPs (KORA F4). The counts for
PSEA on individual genotypes and phenotype measurements (PSEA-GENO)
and for PSEA based on GWAS results (PSEA-GWAS) are presented. For
better comparability genes that were not represented in the pruned data are
also excluded form the counts for not-pruned data.
PSEA-GENO PSEA-GWAS
KORA F4 not pruned KORA F4 pruned KORA F4 not pruned KORA F4 pruned
number of genes number of genes number of genes number of genes
identiﬁed previous identiﬁed previous identiﬁed previous identiﬁed previous
gene 269 43 274 43 56 22 159 34
gene group 70 15 71 15 16 7 48 12
Table B.5.: Number of genes that were identiﬁed by PSEA on pruned SNPs.
This table compares the number of identiﬁed genes per predeﬁned phenotype
set and the number of previously published genes among those for PSEA
on genotypes and phenotypes (PSEA-GENO) and PSEA on GWAS results
(PSEA-GWAS) for the pruned SNP data.
PSEA on pruned data
number of identiﬁed genes number of previously associated genes
PSEA-GENO PSEA-GWAS percentage PSEA-GENO PSEA-GWAS percentage
set_blood1 86 22 26% 9 5 56%
set_blood2 66 36 55% 9 6 67%
set_blood3 22 14 64% 10 8 80%
set_iron1 81 39 48% 22 8 36%
set_iron2 87 26 30% 25 7 28%
set_iron3 73 37 51% 15 15 100%
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Figure B.1.: QQ-plots of KORA F4 iron and blood trait GWAS results. GWAS
calculated with SNPTEST on the residuals concerning sex and age of all
analyzed iron and blood phenotypes in KORA F4 (stfr: soluble transferrin
receptor, trans sat: transferrin saturation).
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C. Supplementary Information:
Metabolomics Data
Table C.1.: Information on Biocrates metabolites. For each metabolite included in
the analyses the short name, the full biological name and information about
the metabolites class is given.
short name full biochemical name pathway
H1 hexose sugar
Arg arginine amino acids
Gln glutamine amino acids
Gly glycine amino acids
His histidine amino acids
Met methionine amino acids
Orn ornithine amino acids
Phe phenylalanine amino acids
Pro proline amino acids
Ser serine amino acids
Thr threonine amino acids
Trp tryptophan amino acids
Tyr tyrosine amino acids
Val valine amino acids
xLeu leucine/isoleucine amino acids
C0 carnitine carnitine
C2 acetylcarnitine acylcarnitines
C3 propionylcarnitine acylcarnitines
C4 butyrylcarnitine acylcarnitines
C5 valerylcarnitine acylcarnitines
C5.1 tiglylcarnitine acylcarnitines
C6.1 hexenoylcarnitine acylcarnitines
C8 octanoylcarnitine acylcarnitines
C8.1 octenoylcarnitine acylcarnitines
C9 nonaylcarnitine acylcarnitines
C10 decanoylcarnitine acylcarnitines
C10.1 decenoylcarnitine acylcarnitines
C10.2 decadienylcarnitine acylcarnitines
C12 dodecanoylcarnitine acylcarnitines
C12.1 dodecenoylcarnitine acylcarnitines
C14 tetradecanoylcarnitine acylcarnitines
C14.1 tetradecenoylcarnitine acylcarnitines
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C14.2 tetradecadienylcarnitine acylcarnitines
C16 hexadecanoylcarnitine acylcarnitines
C16.1 hexadecenoylcarnitine acylcarnitines
C18 octadecanoylcarnitine acylcarnitines
C18.1 octadecenoylcarnitine acylcarnitines
C18.2 octadecadienylcarnitine acylcarnitines
C3.DC...C4.OH hydroxybutyrylcarnitine hydroxy- and dicarboxy-acylcarnitines
C5.DC...C6.OH glutarylcarnitine (hydroxyhexanoylcarnitine) hydroxy- and dicarboxy-acylcarnitines
C5.M.DC methylglutarylcarnitine hydroxy- and dicarboxy-acylcarnitines
C3.DC.M...C5.OHhydroxyvalerylcarnitine (methylmalonylcarni-
tine)
hydroxy- and dicarboxy-acylcarnitines
C5.1.DC glutaconylcarnitine hydroxy- and dicarboxy-acylcarnitines
C4.1.DC...C6 hexanoylcarnitine (fumarylcarnitine) hydroxy- and dicarboxy-acylcarnitines
C7.DC pimeloylcarnitine hydroxy- and dicarboxy-acylcarnitines
C12.DC dodecanedioylcarnitine hydroxy- and dicarboxy-acylcarnitines
C14.1.OH hydroxytetradecenoylcarnitine hydroxy- and dicarboxy-acylcarnitines
C14.2.OH hydroxytetradecadienylcarnitine hydroxy- and dicarboxy-acylcarnitines
C16.1.OH hydroxyhexadecenoylcarnitine hydroxy- and dicarboxy-acylcarnitines
C16.2.OH hydroxyhexadecadienylcarnitine hydroxy- and dicarboxy-acylcarnitines
SM.C16.0 sphingomyeline C16:0 sphingomyelins
SM.C16.1 sphingomyeline C16:1 sphingomyelins
SM.C18.0 sphingomyeline C18:0 sphingomyelins
SM.C18.1 sphingomyeline C18:1 sphingomyelins
SM.C20.2 sphingomyeline C20:2 sphingomyelins
SM.C24.0 sphingomyeline C24:0 sphingomyelins
SM.C24.1 sphingomyeline C24:1 sphingomyelins
SM.C26.0 sphingomyeline C26:0 sphingomyelins
SM.C26.1 sphingomyeline C26:1 sphingomyelins
SM..OH..C14.1 hydroxysphingomyeline C14:1 hydroxysphingomyelins
SM..OH..C16.1 hydroxysphingomyeline C16:1 hydroxysphingomyelins
SM..OH..C22.1 hydroxysphingomyeline C22:1 hydroxysphingomyelins
SM..OH..C22.2 hydroxysphingomyeline C22:2 hydroxysphingomyelins
SM..OH..C24.1 hydroxysphingomyeline C24:1 hydroxysphingomyelins
PC.aa.C24.0 phosphatidylcholine diacyl C24:0 diacyl-phosphatidylcholines
PC.aa.C26.0 phosphatidylcholine diacyl C26:0 diacyl-phosphatidylcholines
PC.aa.C28.1 phosphatidylcholine diacyl C28:1 diacyl-phosphatidylcholines
PC.aa.C30.0 phosphatidylcholine diacyl C30:0 diacyl-phosphatidylcholines
PC.aa.C32.0 phosphatidylcholine diacyl C32:0 diacyl-phosphatidylcholines
PC.aa.C32.1 phosphatidylcholine diacyl C32:1 diacyl-phosphatidylcholines
PC.aa.C32.2 phosphatidylcholine diacyl C32:2 diacyl-phosphatidylcholines
PC.aa.C32.3 phosphatidylcholine diacyl C32:3 diacyl-phosphatidylcholines
PC.aa.C34.1 phosphatidylcholine diacyl C34:1 diacyl-phosphatidylcholines
PC.aa.C34.2 phosphatidylcholine diacyl C34:2 diacyl-phosphatidylcholines
PC.aa.C34.3 phosphatidylcholine diacyl C34:3 diacyl-phosphatidylcholines
PC.aa.C34.4 phosphatidylcholine diacyl C34:4 diacyl-phosphatidylcholines
PC.aa.C36.0 phosphatidylcholine diacyl C36:0 diacyl-phosphatidylcholines
PC.aa.C36.1 phosphatidylcholine diacyl C36:1 diacyl-phosphatidylcholines
PC.aa.C36.2 phosphatidylcholine diacyl C36:2 diacyl-phosphatidylcholines
PC.aa.C36.3 phosphatidylcholine diacyl C36:3 diacyl-phosphatidylcholines
PC.aa.C36.4 phosphatidylcholine diacyl C36:4 diacyl-phosphatidylcholines
PC.aa.C36.5 phosphatidylcholine diacyl C36:5 diacyl-phosphatidylcholines
PC.aa.C36.6 phosphatidylcholine diacyl C36:6 diacyl-phosphatidylcholines
PC.aa.C38.0 phosphatidylcholine diacyl C38:0 diacyl-phosphatidylcholines
PC.aa.C38.3 phosphatidylcholine diacyl C38:3 diacyl-phosphatidylcholines
PC.aa.C38.4 phosphatidylcholine diacyl C38:4 diacyl-phosphatidylcholines
PC.aa.C38.5 phosphatidylcholine diacyl C38:5 diacyl-phosphatidylcholines
PC.aa.C38.6 phosphatidylcholine diacyl C38:6 diacyl-phosphatidylcholines
PC.aa.C40.1 phosphatidylcholine diacyl C40:1 diacyl-phosphatidylcholines
PC.aa.C40.2 phosphatidylcholine diacyl C40:2 diacyl-phosphatidylcholines
PC.aa.C40.3 phosphatidylcholine diacyl C40:3 diacyl-phosphatidylcholines
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PC.aa.C40.4 phosphatidylcholine diacyl C40:4 diacyl-phosphatidylcholines
PC.aa.C40.5 phosphatidylcholine diacyl C40:5 diacyl-phosphatidylcholines
PC.aa.C40.6 phosphatidylcholine diacyl C40:6 diacyl-phosphatidylcholines
PC.aa.C42.0 phosphatidylcholine diacyl C42:0 diacyl-phosphatidylcholines
PC.aa.C42.1 phosphatidylcholine diacyl C42:1 diacyl-phosphatidylcholines
PC.aa.C42.2 phosphatidylcholine diacyl C42:2 diacyl-phosphatidylcholines
PC.aa.C42.4 phosphatidylcholine diacyl C42:4 diacyl-phosphatidylcholines
PC.aa.C42.5 phosphatidylcholine diacyl C42:5 diacyl-phosphatidylcholines
PC.aa.C42.6 phosphatidylcholine diacyl C42:6 diacyl-phosphatidylcholines
PC.ae.C30.0 phosphatidylcholine acyl-alkyl C30:0 acyl-alkyl-phosphatidylcholines
PC.ae.C30.2 phosphatidylcholine acyl-alkyl C30:2 acyl-alkyl-phosphatidylcholines
PC.ae.C32.1 phosphatidylcholine acyl-alkyl C32:1 acyl-alkyl-phosphatidylcholines
PC.ae.C32.2 phosphatidylcholine acyl-alkyl C32:2 acyl-alkyl-phosphatidylcholines
PC.ae.C34.0 phosphatidylcholine acyl-alkyl C34:0 acyl-alkyl-phosphatidylcholines
PC.ae.C34.1 phosphatidylcholine acyl-alkyl C34:1 acyl-alkyl-phosphatidylcholines
PC.ae.C34.2 phosphatidylcholine acyl-alkyl C34:2 acyl-alkyl-phosphatidylcholines
PC.ae.C34.3 phosphatidylcholine acyl-alkyl C34:3 acyl-alkyl-phosphatidylcholines
PC.ae.C36.0 phosphatidylcholine acyl-alkyl C36:0 acyl-alkyl-phosphatidylcholines
PC.ae.C36.1 phosphatidylcholine acyl-alkyl C36:1 acyl-alkyl-phosphatidylcholines
PC.ae.C36.2 phosphatidylcholine acyl-alkyl C36:2 acyl-alkyl-phosphatidylcholines
PC.ae.C36.3 phosphatidylcholine acyl-alkyl C36:3 acyl-alkyl-phosphatidylcholines
PC.ae.C36.4 phosphatidylcholine acyl-alkyl C36:4 acyl-alkyl-phosphatidylcholines
PC.ae.C36.5 phosphatidylcholine acyl-alkyl C36:5 acyl-alkyl-phosphatidylcholines
PC.ae.C38.0 phosphatidylcholine acyl-alkyl C38:0 acyl-alkyl-phosphatidylcholines
PC.ae.C38.1 phosphatidylcholine acyl-alkyl C38:1 acyl-alkyl-phosphatidylcholines
PC.ae.C38.2 phosphatidylcholine acyl-alkyl C38:2 acyl-alkyl-phosphatidylcholines
PC.ae.C38.3 phosphatidylcholine acyl-alkyl C38:3 acyl-alkyl-phosphatidylcholines
PC.ae.C38.4 phosphatidylcholine acyl-alkyl C38:4 acyl-alkyl-phosphatidylcholines
PC.ae.C38.5 phosphatidylcholine acyl-alkyl C38:5 acyl-alkyl-phosphatidylcholines
PC.ae.C38.6 phosphatidylcholine acyl-alkyl C38:6 acyl-alkyl-phosphatidylcholines
PC.ae.C40.0 phosphatidylcholine acyl-alkyl C40:0 acyl-alkyl-phosphatidylcholines
PC.ae.C40.1 phosphatidylcholine acyl-alkyl C40:1 acyl-alkyl-phosphatidylcholines
PC.ae.C40.2 phosphatidylcholine acyl-alkyl C40:2 acyl-alkyl-phosphatidylcholines
PC.ae.C40.3 phosphatidylcholine acyl-alkyl C40:3 acyl-alkyl-phosphatidylcholines
PC.ae.C40.4 phosphatidylcholine acyl-alkyl C40:4 acyl-alkyl-phosphatidylcholines
PC.ae.C40.5 phosphatidylcholine acyl-alkyl C40:5 acyl-alkyl-phosphatidylcholines
PC.ae.C40.6 phosphatidylcholine acyl-alkyl C40:6 acyl-alkyl-phosphatidylcholines
PC.ae.C42.0 phosphatidylcholine acyl-alkyl C42:0 acyl-alkyl-phosphatidylcholines
PC.ae.C42.1 phosphatidylcholine acyl-alkyl C42:1 acyl-alkyl-phosphatidylcholines
PC.ae.C42.2 phosphatidylcholine acyl-alkyl C42:2 acyl-alkyl-phosphatidylcholines
PC.ae.C42.3 phosphatidylcholine acyl-alkyl C42:3 acyl-alkyl-phosphatidylcholines
PC.ae.C42.4 phosphatidylcholine acyl-alkyl C42:4 acyl-alkyl-phosphatidylcholines
PC.ae.C42.5 phosphatidylcholine acyl-alkyl C42:5 acyl-alkyl-phosphatidylcholines
PC.ae.C44.3 phosphatidylcholine acyl-alkyl C44:3 acyl-alkyl-phosphatidylcholines
PC.ae.C44.4 phosphatidylcholine acyl-alkyl C44:4 acyl-alkyl-phosphatidylcholines
PC.ae.C44.5 phosphatidylcholine acyl-alkyl C44:5 acyl-alkyl-phosphatidylcholines
PC.ae.C44.6 phosphatidylcholine acyl-alkyl C44:6 acyl-alkyl-phosphatidylcholines
lysoPC.a.C14.0 lysophosphatidylcholine acyl C14:0 lyso-phosphatidylcholines
lysoPC.a.C16.0 lysophosphatidylcholine acyl C16:0 lyso-phosphatidylcholines
lysoPC.a.C16.1 lysophosphatidylcholine acyl C16:1 lyso-phosphatidylcholines
lysoPC.a.C17.0 lysophosphatidylcholine acyl C17:0 lyso-phosphatidylcholines
lysoPC.a.C18.0 lysophosphatidylcholine acyl C18:0 lyso-phosphatidylcholines
lysoPC.a.C18.1 lysophosphatidylcholine acyl C18:1 lyso-phosphatidylcholines
lysoPC.a.C18.2 lysophosphatidylcholine acyl C18:2 lyso-phosphatidylcholines
lysoPC.a.C20.3 lysophosphatidylcholine acyl C20:3 lyso-phosphatidylcholines
lysoPC.a.C20.4 lysophosphatidylcholine acyl C20:4 lyso-phosphatidylcholines
lysoPC.a.C24.0 lysophosphatidylcholine acyl C24:0 lyso-phosphatidylcholines
lysoPC.a.C26.1 lysophosphatidylcholine acyl C26:1 lyso-phosphatidylcholines
lysoPC.a.C28.0 lysophosphatidylcholine acyl C28:0 lyso-phosphatidylcholines
lysoPC.a.C28.1 lysophosphatidylcholine acyl C28:1 lyso-phosphatidylcholines
65
C. Supplementary Information: Metabolomics Data
Table C.2.: Information on Metabolon metabolites. For each metabolite included
in the analyses the short name, a long name and the information about super-
and subpathway is given.
short name full biochemical name superpathway subpathway
ALANINE alanine amino acid alanine and aspartate metabolism
ALPHAHYD alpha-hydroxyisovalerate amino acid valine, leucine and isoleucine metabolism
ARGININE arginine amino acid urea cycle; arginine-, proline-, metabolism
ASPARAGI asparagine amino acid alanine and aspartate metabolism
ASPARTAT aspartate amino acid alanine and aspartate metabolism
BETAINE betaine amino acid glycine, serine and threonine metabolism
CGLYCOSY c-glycosyltryptophan amino acid tryptophan metabolism
CITRULLI citrulline amino acid urea cycle; arginine-, proline-, metabolism
CREATINE creatine amino acid creatine metabolism
CREATINI creatinine amino acid creatine metabolism
CYSTEINE cysteine amino acid cysteine, methionine, SAM, taurine
metabolism
DIMETHYL dimethylarginine amino acid urea cycle; arginine-, proline-, metabolism
GLUTAMAT glutamate amino acid glutamate metabolism
GLUTAMIN glutamine amino acid glutamate metabolism
GLYCINE glycine amino acid glycine, serine and threonine metabolism
HISTIDIN histidine amino acid histidine metabolism
INDOLEAC indoleacetate amino acid tryptophan metabolism
INDOLEPR indolepropionate amino acid tryptophan metabolism
ISOLEUCI isoleucine amino acid valine, leucine and isoleucine metabolism
KYNURENI kynurenine amino acid tryptophan metabolism
LEUCINE leucine amino acid valine, leucine and isoleucine metabolism
LYSINE lysine amino acid lysine metabolism
METHIONI methionine amino acid cysteine, methionine, SAM, taurine
metabolism
NACETYLA N-acetylornithine amino acid valine, leucine and isoleucine metabolism
NACETYLO N-acetylornithine amino acid urea cycle; arginine-, proline-, metabolism
ORNITHIN ornithine amino acid urea cycle; arginine-, proline-, metabolism
PCRESOLS p-cresol amino acid phenylalanine and tyrosine metabolism
PHENYLAL phenylalanine amino acid phenylalanine and tyrosine metabolism
PIPECOLA pipecolate amino acid lysine metabolism
PROLINE proline amino acid urea cycle; arginine-, proline-, metabolism
PYROGLUT pyroglutamine amino acid glutamate metabolism
SERINE serine amino acid glycine, serine and threonine metabolism
SEROTONI serotonin amino acid tryptophan metabolism
STACHYDR stachydrine amino acid urea cycle; arginine-, proline-, metabolism
THREONIN threonine amino acid glycine, serine and threonine metabolism
TRANS4HY hydroxyproline amino acid urea cycle; arginine-, proline-, metabolism
TRYPTOPH tryptophan amino acid tryptophan metabolism
TYROSINE tyrosine amino acid phenylalanine and tyrosine metabolism
UREA urea amino acid urea cycle; arginine-, proline-, metabolism
V104_A 3-methyl-2-oxopentanoate amino acid valine, leucine and isoleucine metabolism
V167_A S-glutathionyl-L-cysteine amino acid glutathione metabolism
V285_A phenylacetylglutamine amino acid phenylalanine and tyrosine metabolism
V80_A 2-hydroxybutyrate amino acid cysteine, methionine, SAM, taurine
metabolism
V82_A 2-hydroxyisobutyrate amino acid valine, leucine and isoleucine metabolism
VALINE valine amino acid valine, leucine and isoleucine metabolism
X.2AMINOB 2-aminobutyrate amino acid butanoate metabolism
X.34HYDRO 4-hydroxyphenyllactate; amino acid phenylalanine and tyrosine metabolism
X.3INDOXY indoxyl sulfate amino acid tryptophan metabolism
X.3METHYL 3-methyl-2-oxobutanoate amino acid valine, leucine and isoleucine metabolism
X.4ACETAM 4-acetamidobutanoate amino acid guanidino and acetamido metabolism
X.4METHYL 4-methyl-2-oxopentanoate amino acid valine, leucine and isoleucine metabolism
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X.5OXOPRO 5-oxoproline amino acid glutathione metabolism
ARABITOL arabitol carbohydrate nucleotide sugars, pentose metabolism
ERYTHRON erythronate carbohydrate aminosugars metabolism
FRUCTOSE fructose carbohydrate fructose, mannose, galactose, starch, and
sucrose metabolism
GLUCOSE glucose carbohydrate glycolysis, gluconeogenesis, pyruvate
metabolism
GLYCERAT glycerate carbohydrate glycolysis, gluconeogenesis, pyruvate
metabolism
LACTATE lactate carbohydrate glycolysis, gluconeogenesis, pyruvate
metabolism
MANNOSE mannose carbohydrate fructose, mannose, galactose, starch, and
sucrose metabolism
PYRUVATE pyruvate carbohydrate glycolysis, gluconeogenesis, pyruvate
metabolism
THREITOL threitol carbohydrate nucleotide sugars, pentose metabolism
X.15ANHYD 1,5-anhydro-D-glucitol carbohydrate glycolysis, gluconeogenesis, pyruvate
metabolism
ALPHATOC alpha-tocopherol cofactors and vita-
mins
tocopherol metabolism
BILIRUBI bilirubin (E;E) cofactors and vita-
mins
hemoglobin and porphyrin metabolism
HEME heme cofactors and vita-
mins
hemoglobin and porphyrin
PANTOTHE pantothenate cofactors and vita-
mins
pantothenate and CoA metabolism
PYRIDOXA 4-pyridoxate cofactors and vita-
mins
vitamin B6 metabolism
THREONAT threonate cofactors and vita-
mins
ascorbate and aldarate metabolism
V144_A bilirubin (Z;Z) cofactors and vita-
mins
hemoglobin and porphyrin metabolism
ACETYLPH acetylphosphate energy oxidative phosphorylation
CITRATE citrate energy krebs cycle
PHOSPHAT phosphate energy oxidative phosphorylation
ADRENATE fatty acid
22:4(7Z,10Z,13Z,16Z)
lipid fatty acid, polyene
ANDROSTE androsterone sulfate lipid sterol/steroid
ARACHIDO fatty acid
20:4(5Z,8Z,11Z,14Z)
lipid fatty acid, polyene
BUTYRYLC carnitine 4:0 lipid carnitine metabolism
CAPRATE1 fatty acid 10:0 lipid fatty acid, saturated, even
CAPROATE fatty acid 6:0 lipid fatty acid, saturated, even
CAPRYLAT fatty acid 8:0 lipid fatty acid, saturated, even
CARNITIN carnitine lipid carnitine metabolism
CHOLESTE cholesterol lipid sterol/steroid
CHOLINE choline lipid glycerolipid metabolism
CORTISOL cortisol lipid sterol/steroid
CORTISON cortisone lipid sterol/steroid
DECANOYL carnitine 10:0 lipid carnitine metabolism
DEHYDROI dehydroepiandrosterone
sulfate
lipid sterol/steroid
DIHOMOLI fatty acid 20:2(11Z,14Z) lipid fatty acid, polyene
DOCOSAHE fatty acid
22:6(4Z,7Z,10Z,13Z,16Z,19Z)
lipid fatty acid, polyene
DOCOSAPE fatty acid
22:5(7Z,10Z,13Z,16Z,19Z)
lipid fatty acid, polyene
EICOSAPE fatty acid
20:5(5Z,8Z,11Z,14Z,17Z)
lipid fatty acid, polyene
EICOSENO fatty acid 20:1(9Z/11Z) lipid fatty acid, monoene
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EPIANDRO epiandrosterone sulfate lipid sterol/steroid
GLUTAROY glutaroyl carnitine lipid carnitine metabolism
GLYCEROL glycerol lipid glycerolipid metabolism
GLYCEROP glycerophosphorylcholine lipid glycerolipid metabolism
HEPTANOA fatty acid 7:0 lipid fatty acid, saturated, odd
HEXANOYL carnitine 6:0 lipid carnitine metabolism
ISOBUTYR isobutyrylcarnitine lipid carnitine metabolism
ISOVALER isovalerate lipid fatty acid metabolism
LAURATE1 fatty acid 12:0 lipid fatty acid, saturated, even
LINOLEAM linoleamide 18:2(9Z,12Z) lipid fatty acid amide
LINOLEAT fatty acid 18:2(9Z,12Z) lipid fatty acid, polyene
LINOLENA fatty acid 18:3(n-3/n-6) lipid fatty acid, polyene
MARGARAT fatty acid 17:0 lipid fatty acid, saturated, odd
MYOINOSI myo-inositol lipid inositol metabolism
MYRISTAT fatty acid 14:0 lipid fatty acid, saturated, even
MYRISTOL fatty acid 14:1(9Z) lipid fatty acid, monoene
NONADECA fatty acid 9:0 lipid fatty acid, saturated, odd
OCTANOYL carnitine 8:0 lipid carnitine metabolism
OLEAMIDE oleamide 18:2(9Z) lipid fatty acid, amide
OLEATE18 fatty acid 18:1(9Z) lipid fatty acid, monoene
OLEOYLCA carnitine 18:1(9Z) lipid carnitine metabolism
PALMITAT fatty acid 16:0 lipid fatty acid, saturated, even
PALMITOL fatty acid 16:1(9Z) lipid fatty acid, monoene
PALMITOY carnitine 16:0 lipid carnitine metabolism
PELARGON fatty acid 9:0 lipid fatty acid, saturated, odd
PENTADEC fatty acid 15:0 lipid fatty acid, saturated, odd
PROPIONY carnitine 3:0 lipid carnitine metabolism
STEARATE fatty acid 18:0 lipid fatty acid, saturated, even
STEARIDO fatty acid
18:4(6Z,9Z,12Z,15Z)
lipid fatty acid, polyene
THROMBOX thromboxane B2 lipid eicosanoid
UNDECANO fatty acid 11:0 lipid fatty acid, saturated, odd
V100_A 3-hydroxybutyrate lipid ketone bodies
V119_A acetylcarnitine lipid carnitine metabolism
V173_A fatty acid 20:3(n-3/n-6) lipid fatty acid, polyene
V204_A glycerol 3-phosphate lipid glycerolipid metabolism
V235_A isovalerylcarnitine lipid carnitine metabolism
V47_A PE(20:4(5Z,8Z,11Z,14Z)-
/0:0)
lipid glycerolipid metabolism
V48_A PI(20:4(5Z,8Z,11Z,14Z)-
/0:0)
lipid glycerolipid metabolism
V51_A PC(20:3(8Z,11Z,14Z)/0:0) lipid glycerolipid metabolism
V54_A PC(18:2(9Z,12Z)/0:0) lipid glycerolipid metabolism
V55_A PE(18:2(9Z,12Z)/0:0) lipid lysolipid
V60_A PC(18:1(9Z)/0:0) lipid glycerolipid metabolism
V61_A PE(18:1(9Z)) lipid glycerolipid metabolism
V63_A glycerol(16:0/0:0/0:0) lipid monoacylglycerol
V64_A PC(16:0/0:0) lipid glycerolipid metabolism
V65_A PE(16:0/0:0) lipid glycerolipid metabolism
V68_A PC(18:0/0:0) lipid glycerolipid metabolism
V70_A PI(18:0/0:0) lipid glycerolipid metabolism
V83_A hydroxy fatty acid 16:0 lipid fatty acid, saturated, monohydroxy
V84_A hydroxy fatty acid 18:0 lipid fatty acid, saturated, monohydroxy
X.10HEPTA fatty acid 17:1(10Z) lipid fatty acid, monoene, odd
X.10NONAD fatty acid 19:1(10Z) lipid fatty acid, monoene, odd
X.10UNDEC fatty acid 11:1(10Z) lipid fatty acid, monoene, odd
X.1ARACHI PC(20:4(5Z,8Z,11Z,14Z)-
/0:0)
lipid glycerolipid metabolism
X.1DOCOSA PC(22:6(4Z,7Z,10Z,13Z,-
16Z,19Z)/0:0)
lipid glycerolipid metabolism
X.1EICOSA PC(20:2(11Z,14Z)/0:0) lipid lysolipid
X.1HEPTAD PC(17:0/0:0) lipid glycerolipid metabolism
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X.1LINOLE glycerol(18:2(9Z,12Z)/0:0-
/0:0)
lipid monoacylglycerol
X.1MYRIST PC(14:0/0:0) lipid glycerolipid metabolism
X.1OLEOYL glycerol(18:1(9Z)/0:0/0:0) lipid monoacylglycerol
X.1PALMIT PC(16:1(9Z)/0:0) lipid glycerolipid metabolism
X.2LINOLE PC(0:0/18:2(9Z,12Z)) lipid glycerolipid metabolism
X.2METHYL 2-methylbutyroylcarnitine lipid carnitine metabolism
X.2OLEOYL PC(0:0/18:1(9Z)) lipid glycerolipid metabolism
X.2PALMIT PC(0:0/16:0) lipid glycerolipid metabolism
X.2STEARO PC(0:0/18:0) lipid glycerolipid metabolism
X.2TETRAD 2-tetradecenoyl carnitine lipid carnitine metabolism
X.3CARBOX 3-carboxy-4-methyl-5-
propyl-2-furanpropanoate
lipid fatty acid, furan, dicarboxylate
X.3DEHYDR 3-dehydrocarnitine lipid carnitine metabolism
X.5DODECE fatty acid 12:0(5Z) lipid fatty acid, monoene
X.7ALPHAH 7-hoca lipid sterol/steroid
GUANOSIN guanosine nucleotide purine metabolism, guanine containing
HYPOXANT hypoxanthine nucleotide purine metabolism,
(hypo)xanthine/inosine containing
INOSINE inosine nucleotide purine metabolism,
(hypo)xanthine/inosine containing
N1METHYL 1-methyladenosine nucleotide purine metabolism, adenine containing
PSEUDOUR pseudouridine nucleotide pyrimidine metabolism, uracil containing
URATE urate nucleotide purine metabolism, urate metabolism
URIDINE uridine nucleotide pyrimidine metabolism, uracil containing
X.7METHYL 7-methylguanine nucleotide purine metabolism, guanine containing
XANTHINE xanthine nucleotide purine metabolism,
(hypo)xanthine/inosine containing
ADPSGEGD ADpSGEGDFXAEGGG-
VR
peptide ﬁbrinogen cleavage peptide
ADSGEGDF ADSGEGDFXAEGGG-
VR
peptide ﬁbrinogen cleavage peptide
ASPARTYL aspartyl-phenylalanine peptide dipeptide
DSGEGDFX DSGEGDFXAEGGGVR peptide ﬁbrinogen cleavage peptide
HWESASXX HWESASXX peptide polypeptide
PROHYDRO pro-hydroxy-pro peptide dipeptide
V188_A gamma-glutamyl-
glutamine
peptide g-glutamyl
V190_A gamma-glutamyl-leucine peptide g-glutamyl
V192_A gamma-glutamyl-
phenylalanine
peptide g-glutamyl
V194_A gamma-glutamyl-tyrosine peptide g-glutamyl
V195_A gamma-glutamyl-valine peptide dipeptide
BENZOATE benzoate xenobiotics benzoate metabolism
CAFFEINE caﬀeine xenobiotics xanthine metabolism
CATECHOL catecholsulfate xenobiotics benzoate metabolism
ERYTHRIT erythritol xenobiotics sugar, sugar substitute, starch
HIPPURAT hippurate xenobiotics benzoate metabolism
PARAXANT paraxanthine xenobiotics xanthine metabolism
PHENOLSU phenylsulfate xenobiotics chemical
PIPERINE piperine xenobiotics food component/plant
THEOBROM theobromine xenobiotics xanthine metabolism
THEOPHYL theophylline xenobiotics xanthine metabolism
X.4VINYLP 4-vinylphenylsulfate xenobiotics benzoate metabolism
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Table C.3.: GGM-deﬁned phenotype sets on Biocrates metabolites. Phenotype
sets estimated with the GGM on Biocrates metabolites in KORA F4. These
sets were analyzed for enrichment with PSEA in KORA F4. Replication was
performed in TwinsUK data.
set name elements of the metabolite set
set_1_b C0, C3
set_2_b C10, C10.1, C10.2, C12, C12.1, C14, C14.1, C14.2, C16, C18, C18.1, C18.2, C2,
C4.1.DC...C6, C8
set_3_b C14.1.OH, C7.DC
set_4_b C5.M.DC, C5.1.DC, C6.1
set_5_b Gly, Ser, Thr
set_6_b Met, Trp, Tyr
set_7_b Val, xLeu
set_8_b PC.aa.C24.0, PC.aa.C26.0, lysoPC.a.C24.0, lysoPC.a.C26.1, lysoPC.a.C28.1
set_9_b PC.aa.C28.1, PC.ae.C34.1, PC.ae.C36.1, SM..OH..C14.1, SM..OH..C16.1, SM..OH..C22.1,
SM..OH..C22.2, SM..OH..C24.1, SM.C16.0, SM.C16.1, SM.C18.0, SM.C18.1, SM.C24.0,
SM.C24.1, SM.C26.0, SM.C26.1
set_10_b PC.aa.C30.0, PC.aa.C32.0, PC.ae.C30.0
set_11_b PC.aa.C32.1, PC.aa.C34.1, PC.aa.C34.2, PC.aa.C36.1, PC.aa.C36.2, PC.aa.C36.3,
PC.aa.C36.4, PC.aa.C36.5, PC.aa.C38.3, PC.aa.C38.4, PC.aa.C38.5, PC.aa.C38.6,
PC.aa.C40.4, PC.aa.C40.5, PC.aa.C40.6, PC.ae.C38.3, PC.ae.C40.0, PC.ae.C40.6,
PC.ae.C42.0, lysoPC.a.C16.0, lysoPC.a.C16.1, lysoPC.a.C17.0, lysoPC.a.C18.0,
lysoPC.a.C18.1, lysoPC.a.C18.2, lysoPC.a.C20.3, lysoPC.a.C20.4
set_12_b PC.aa.C32.2, PC.aa.C34.4, PC.aa.C36.6, PC.ae.C38.0, PC.ae.C40.1, PC.ae.C40.2,
PC.ae.C42.2, PC.ae.C42.3
set_13_b PC.aa.C32.3, PC.aa.C34.3
set_14_b PC.aa.C36.0, PC.aa.C38.0, PC.aa.C42.0, PC.aa.C42.1, PC.ae.C34.2, PC.ae.C34.3,
PC.ae.C36.3, PC.ae.C36.4, PC.ae.C36.5, PC.ae.C38.4, PC.ae.C38.5, PC.ae.C38.6,
PC.ae.C40.4, PC.ae.C40.5, PC.ae.C42.4, PC.ae.C42.5, PC.ae.C44.4, PC.ae.C44.5,
PC.ae.C44.6
set_15_b PC.aa.C40.2, PC.aa.C40.3, PC.aa.C42.5, PC.aa.C42.6
set_16_b PC.ae.C32.1, PC.ae.C32.2
set_17_b C10, C8
set_18_b C18.1, C18.2
set_19_b PC.aa.C24.0, PC.aa.C26.0
set_20_b PC.aa.C30.0, PC.aa.C32.0
set_21_b PC.aa.C32.1, lysoPC.a.C16.1
set_22_b PC.aa.C34.2, PC.aa.C36.2
set_23_b PC.aa.C36.4, PC.aa.C38.4
set_24_b PC.aa.C36.5, PC.aa.C38.5, PC.aa.C40.4, PC.aa.C40.5
set_25_b PC.aa.C36.6, PC.ae.C38.0
set_26_b PC.aa.C38.0, PC.ae.C38.6
set_27_b PC.aa.C38.6, PC.aa.C40.6
set_28_b PC.aa.C40.2, PC.aa.C40.3
set_29_b PC.ae.C34.2, PC.ae.C36.3
set_30_b PC.ae.C34.3, PC.ae.C36.5
set_31_b PC.ae.C36.4, PC.ae.C38.5
set_32_b PC.ae.C38.4, PC.ae.C40.4, PC.ae.C42.4
set_33_b PC.ae.C42.5, PC.ae.C44.4, PC.ae.C44.5
set_34_b lysoPC.a.C16.0, lysoPC.a.C18.0
set_35_b lysoPC.a.C20.3, lysoPC.a.C20.4
set_36_b SM..OH..C14.1, SM..OH..C16.1
set_37_b SM..OH..C22.1, SM..OH..C22.2, SM.C24.0, SM.C24.1
set_38_b SM.C16.0, SM.C16.1, SM.C18.0, SM.C18.1
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Table C.4.: GGM-deﬁned phenotype sets on Metabolon metabolites. Pheno-
type sets estimated with the GGM on Metabolon metabolites in KORA F4.
These sets were analyzed for enrichment with PSEA in KORA F4. For the
replication in TwinsUK two metabolites were not available, these and the
corresponding sets are marked with stars.
set name elements of the metabolite set
*set_1_m* X.1ARACHI, V47_A, X.1DOCOSA, X.1EICOSA, V51_A, V54_A, V55_A, V60_A,
V64_A, V68_A, X.2LINOLE, X.2OLEOYL, X.2PALMIT, X.2STEARO, X.3CARBOX,
ARACHIDO, V173_A, DOCOSAHE, *LINOLEAM*, *OLEAMIDE*
set_2_m V48_A, V70_A
set_3_m X.1LINOLE, X.1OLEOYL
set_4_m X.1MYRIST, X.1PALMIT
set_5_m V61_A, V65_A
set_6_m X.10HEPTA, X.10NONAD, X.5DODECE, MARGARAT, MYRISTOL, PALMITOL
set_7_m X.2AMINOB, V80_A
set_8_m V83_A, V84_A
set_9_m X.2TETRAD, DECANOYL, HEXANOYL, OCTANOYL
set_10_m X.34HYDRO, ALPHAHYD
set_11_m V100_A, ALANINE
set_12_m X.3INDOXY, PCRESOLS, V285_A
set_13_m X.3METHYL, V104_A, X.4METHYL, ISOLEUCI, LEUCINE, VALINE
set_14_m V119_A, PROPIONY
set_15_m ACETYLPH, CHOLESTE, PHOSPHAT
set_16_m ADSGEGDF, DSGEGDFX
set_17_m ANDROSTE, EPIANDRO
set_18_m ASPARTAT, CYSTEINE
set_19_m BETAINE, CHOLINE
set_20_m BILIRUBI, V144_A
set_21_m CAFFEINE, PARAXANT, THEOPHYL
set_22_m CAPRATE1, CAPROATE, CAPRYLAT, HEPTANOA, PELARGON
set_23_m CATECHOL, HIPPURAT
set_24_m CORTISOL, CORTISON
set_25_m CREATINE, PYROGLUT
set_26_m DEHYDROI, THROMBOX
set_27_m DIHOMOLI, EICOSENO, LINOLEAT, LINOLENA, STEARIDO
set_28_m DOCOSAPE, EICOSAPE
set_29_m V188_A, GLUTAMIN
set_30_m V194_A, TYROSINE
set_31_m GLUCOSE, MANNOSE
set_32_m GLYCERAT, THREONAT
set_33_m GLYCINE, SERINE
set_34_m GUANOSIN, INOSINE
set_35_m ISOVALER, V235_A
set_36_m LAURATE1, MYRISTAT
set_37_m OLEATE18, PALMITAT
set_38_m OLEOYLCA, PALMITOY
set_39_m PANTOTHE, PYRIDOXA
set_40_m X.1ARACHI, V47_A, X.1DOCOSA, V55_A, DOCOSAHE
set_41_m V51_A, V173_A
set_42_m V54_A, X.2PALMIT
set_43_m X.10HEPTA, PALMITOL
*set_44_m* X.2STEARO, *LINOLEAM*, *OLEAMIDE*
set_45_m V104_A, X.4METHYL, ISOLEUCI, LEUCINE
set_46_m CHOLESTE, PHOSPHAT
set_47_m DECANOYL, HEXANOYL, OCTANOYL
set_48_m HEPTANOA, PELARGON
set_49_m PCRESOLS, V285_A
set_50_m PARAXANT, THEOPHYL
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Figure C.1.: Permutation scheme of PSEA for predeﬁned metabolite sets.
This ﬁgure visualizes the stepwise permutation scheme and replication that
was used in application of PSEA on predeﬁned metabolite sets. For both
metabolite panels, Biocrates and Metabolon, the same permutation strategy
was applied.
Table C.5.: PSEA results on Metabolon metabolites for sets diﬀering in KORA
F4 and TwinsUK. For the presented genes the given phenotype sets showed
an enrichment with a p-value below 10−4 in PSEA on KORA F4 and were not
replicable in TwinsUK data. The phenotype set_1_m had to be modiﬁed
for replication in TwinsUK and it was not possible to test set_44_m in
TwinsUK. Gene groups are separated with background color.
chr. start pos. stop pos. phenotype sets (set_*_m)
3 15143274 15467811 44
genes COL6A4P1, SH3BP5
8 87838015 88501537 44
genes CNBD1
11 61094821 61527475 1
genes FEN1, C11orf9, DKFZP434K028, MIR1908, MIR611, C11orf10, FADS1, DAGLA,
FADS2, BEST1, FADS3
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D. Supplementary Information: New
Identﬁed Phenotype Sets
Figure D.1.: Permutation scheme of PSEA for new identifed metabolite sets.
This ﬁgure visualizes the stepwise permutation scheme with intermediate
replication that was used in application of PSEA with the extension of new
identﬁcation of metabolite sets. For both metabolite panels, Biocrates and
Metabolon, the same permutation strategy was applied.
D.1. New Identiﬁed Metabolite Sets
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Table D.3.: Signiﬁcant enriched new phenotype sets without possibility of repli-
cation in TwinsUK. All new identiﬁed phenotype sets that were signliﬁ-
cantly enriched in KORA F4 but could not be replicated in TwinsUK data
as the phenotype sets could not be tested in TwinsUK data. num: number
of all metabolites in the metabolite set.
gene P (KORA F4) num elements of the phenotype set
LOC389033 <0.0001 2 ARABITOL GLUCOSE
SNORA62 <0.0001 2 ARABITOL PARAXANT
ATXN7 <0.0001 2 STACHYDR THREONAT
C3orf49 <0.0001 2 STACHYDR THREONAT
THOC7 <0.0001 2 STACHYDR THREONAT
BOP1 <0.0001 2 X.15ANHYD OLEAMIDE
GPR172A <0.0001 2 X.15ANHYD OLEAMIDE
HSF1 <0.0001 2 X.15ANHYD OLEAMIDE
KAT5 <0.0001 2 V82_A STACHYDR
RELA <0.0001 2 V82_A STACHYDR
NUP107 <0.0001 2 LINOLEAM LYSINE
SLC35E3 <0.0001 2 LINOLEAM LYSINE
GPR68 <0.0001 2 V144_A LINOLEAM
MIR1197 <0.0001 2 X.4ACETAM STACHYDR
MIR299 <0.0001 2 X.4ACETAM STACHYDR
MIR323 <0.0001 2 X.4ACETAM STACHYDR
MIR329-1 <0.0001 2 X.4ACETAM STACHYDR
MIR329-2 <0.0001 2 X.4ACETAM STACHYDR
MIR380 <0.0001 2 X.4ACETAM STACHYDR
MIR411 <0.0001 2 X.4ACETAM STACHYDR
MIR758 <0.0001 2 X.4ACETAM STACHYDR
SNORD114-8 <0.0001 2 PROPIONY STACHYDR
SNORD114-9 <0.0001 2 PROPIONY STACHYDR
USP50 <0.0001 2 X.3CARBOX LINOLEAM
RAB8B <0.0001 2 X.4ACETAM ARABITOL
RPS27L <0.0001 2 X.4ACETAM ARABITOL
OR4F15 <0.0001 2 X.5DODECE OLEAMIDE
OR4F6 <0.0001 2 X.5DODECE OLEAMIDE
SGK494 <0.0001 2 V80_A ARABITOL
SUPT6H <0.0001 2 V80_A ARABITOL
MED24 <0.0001 2 V61_A STACHYDR
MSL1 <0.0001 2 V61_A STACHYDR
ATP5A1 <0.0001 2 NONADECA OLEAMIDE
MED25 <0.0001 2 V188_A STACHYDR
PTOV1 <0.0001 2 V188_A STACHYDR
TSKS <0.0001 2 V188_A STACHYDR
EIF2S2 <0.0001 2 ARABITOL PROHYDRO
SERINC3 <0.0001 2 ADSGEGDF LINOLEAM
YWHAB <0.0001 2 V70_A STACHYDR
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D.2. Biological Interpretation of New Loci
In the following, all genetic loci that were identiﬁed with PSEA on metabolite data and
were not found in a single phenotype GWAS on the same data are described and set into
biological context.
Genes Identiﬁed on Biocrates Data
IL3 : Interpretation given in section 5.4.
MFSD2A, MYCL1 : At these two overlapping genes on chromosome one the same
phenotype set consisting of ﬁve lyso-phosphatidylcholines of medium chain length (C16
- C20) was identiﬁed, signiﬁcantly enriched and replicated in TwinsUK data. The gene
product of MFSD2A (Major Facilitator Superfamily Domain Containing 2) is a trans-
membrane protein that belongs to a large family of presumptive carbohydrate trans-
porters. Although database analysis of homologs suggests this function, there is no
deﬁnitive proof (Esnault et al., 2008). It is known that MFSD2A is down regulated in
human lung primary tumors and lung cancer cell lines (Spinola et al., 2010). Moreover, a
study described it as receptor for a retrovirus-derived protein (syncytin-2) (Esnault et al.,
2008). MYCL1 is known to be a member of the MYC oncogene family and to be involved
in genesis of small cell lung cancer (Xiong et al., 2011). Carbohydrates are connected
with the fatty acid metabolism via the citrate cycle and with lyso-phosphatidylcholines.
Therefore, the lyso-phosphatidylcholines might support the hypothesis ofMFSD2A being
a carbohydrate transporter.
PDCD6IP : The gene PDCD6IP was identiﬁed with an enrichment of a new identiﬁed
phenotype set consisting of six diﬀerent carnitines (acylcarnitine, hydroxy- and dicar-
boxyacylcarnitines) and three lyso-phosphatidylcholines. The chain length of the selected
acylcarnitines and hydroxyacylcarnitines ranges between 8 and 18 and the chain length of
the lyso-phosphatidylcholines is 16 respectively 18. This gene is named programmed cell
death 6 interacting protein or alternatively ALG-2 (apoptosis-linked-gene-2 product)-
interacting protein X (ALIX). It is known to be involved in various cellular processes, for
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example within the ESCRT (endosomal sorting complex required for transport) pathway
in abscission of cytokinesis, actin-based cytoskeleton assembly and assembly of retro-
viruses (Shibata et al., 2008; Zhou et al., 2010). Another study found, that the coded
protein ALIX controls the function of the lysobisphosphatidic acid (LBPA) in forma-
tion of multivesicular liposomes (Matsuo et al., 2004; Dikic, 2004). The elements of the
enriched phenotype set might be involved in this reaction.
C12orf75 : At gene C12orf75 a set of seven diﬀerent phosphatidylcholines and sphin-
gomyelins along with ﬁve acyl-, hydroxyacyl- or dicarboxyacylcarnitines were identiﬁed
and signiﬁcantly enriched. No gene function is known for C12orf75. The elements of the
enriched phenotype set might hint to an involvement of C12orf75 in lipid metabolism.
DKFZp686O1327 : A set of eleven metabolites of eight metabolite classes, were en-
riched at an uncharacterized region spanning 550 kb on chromosome two. Due to the
diversity of the metabolites in the enriched metabolite set and the unknown gene funtion
no presumption about the gene metabolite network could be made.
Genes Identiﬁed on Metabolon Data
LINGO2 : Interpretation given in section 5.4.
cytochrome P450 family 4: Interpretation given in section 5.4.
CEP68, SLC1A4 : The new identiﬁed phenotype set at the gene CEP68 is a subset
of the phenotype set at SLC1A4. Approximately 63% respectively 65% of the physical
length of these gene regions is overlapping. Both new sets included diﬀerent amino
acids (L-alanine, D-2-aminobutyrate, L-glutamine, L-threonine). The set of SLC1A4
contained a steroid (7-alpha-hydroxy-3-oxo-4-cholestenoate) in addition to these amino
acids. SLC1A4 is a part of the solute carrier family 1, member 4 that is known to function
as amino acid transporter. Arriza et al. (1993) showed that SLC1A4 is a neutral amino
acid transporter with a broad speciﬁcity. Amino acids like alanine and threonine are
eﬀective substrates of the gene product of SLC1A4. Therefore, one could state that
some of the identiﬁed elements in the new sets are cargo of this gene product.
SLC1A4 was found to be associated with multiple system atrophy through the L-serine
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metabolism (Soma et al., 2008). Although, for linkage analysis SLC1A4 was proposed
as candidate gene for bipolar disorder and schizophrenia, association analysis could not
conﬁrm this (Skowronek et al., 2006). For CEP68 less is known. It was found to be a
possible susceptible gene for aspirin intolerance in asthmatics in a Korean cohort (Kim
et al., 2010).
DIRAS3 : The gene DIRAS3 (ARHI ) was identiﬁed for three metabolites of the glyc-
erolipid metabolism (1-oleoylglycerophosphoethanolamine, glycerol and D-glycerate) and
3-methyl-2-oxopentanoate, which is part of the valine, leucine and isoleucine metabolism.
DIRAS3 is a member of the Ras superfamily. Various publications have discussed the
gene as tumor suppressor in diﬀerent types of cancer (Huang et al., 2009; Zou et al.,
2011; Badgwell et al., 2012; Yu et al., 1999). DIRAS3 is assumed to inhibit cell growth
and to play a role in the carcioneogenesis (Huang et al., 2009). Three metabolites in
the identiﬁed set are involved in the glycerolipid metabolism. The remaining metabolite
3-methyl-2-oxopentanoate might be connected with the other metabolites via the citrate
cycle. Possibly, the eﬀect of DIRAS3 on cell growth changes the demand on carbon
sources or energy which modiﬁes glycolysis respectively glycerolipid metabolism.
GCDH and others: Several overlapping genes on chromosome 19 were identiﬁed
(GCDH, CALR, DNASE2, MAST1, PRDX2, RTBDN, DAND5, FARSA, KLF1, NFIX,
RAD23A, SYCE2, GADD45GIP1 ). All enriched sets for these genes include erythritol,
glutaroyl carnitine and one glycerolipid (sn-glycero-3-phosphocholine), other sets include
two additional sugars (β-D-fructose, L-arabitol) and the fatty acid oleamide. The gene
product of GCDH is a glutaryl-CoA dehydrogenase. Glutaryl-CoA is involved in trypto-
phan and lysine degradation and in the fatty acid metabolism. In several steps acetyl-CoA
can be created from the product of glutaryl-CoA dehydrogenase. Carnitine and lipids of
the enriched phenotype sets could reﬂect the involvement of glutaryl-CoA dehydrogenase
in the fatty acids metabolism. The sugars might stem from the connection of acetyl-CoA
with glycolysis. Moreover, GCDH was shown to be associated with mean corpuscular
haemoglobin levels (Ganesh et al., 2009).
miR138-1 : At microRNA 138-1 (miR138-1 ) spanning approximately 150 kb on chro-
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mosome three a set with ﬁve metabolites of diﬀerent glycerolipids, creatinine and the
peptide g-γ-glutamyl was identiﬁed. The miR138 was detected to reduce the expression
of histone H2AX and it induces chromosomal instability after DNA damage (Wang et al.,
2011). MicroRNAs are small RNAs that play an important role in gene regulatory pro-
cesses. Apart from very few microRNAs that show a speciﬁc expression, most microRNAs
regulate diﬀerent genes with various biological functions (Bartel, 2009). The inclusion of
metabolites that are part of diﬀerent pathways in the enriched set, let presume a function
of miR138-1 as a modulator of expression of multiple genes.
UBL3, LOC440131 : The ubiquitin-like 3 (UBL3 ) gene was identiﬁed for a phenotype
set including fatty acids, glycerolipids, amino acids, carnitine, lactate, two steroids and
theophylline. The gene function is not known, but it was reported to be weakly associ-
ated with Biliary atresia (Garcia-Barceló et al., 2010). Ubiquitin-like proteins are proteins
that can be attached to various proteins modifying subsequent processes (Kerscher et al.,
2006). This kind of protein-based modiﬁcation was ﬁrst described for ubiquitin. Numer-
ous reactions can be inﬂuenced by one ubiquitin-like protein (Hochstrasser, 2009). This
could explain the enriched phenotype set, which includes diﬀerent types of metabolites.
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